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Skeletal muscle regeneration following muscle damage is imperative to maintain skeletal 
muscle structure and function throughout the lifespan. Regeneration requires a complex series of 
events including activation of skeletal muscle specific stem cells (satellite cells) followed by 
proliferation and differentiation of committed myoblasts [muscle progenitor cells (MPCs)], and 
formation/repair of functional multinucleated muscle cells. Activation of satellite cells and 
expansion of MPCs is essential to generate a sufficient number of viable cells to repair damaged 
skeletal muscle. In animal models, age is associated with reduced MPC expansion capacity in 
vitro. Additionally, male mouse-MPCs (mMPCs) exhibit higher proliferation rates than female 
mMPCs. However, the impact of age and sex on expansion of human MPCs (hMPCs) remains 
unknown.  
To evaluate the age- and sex-related differences in expansion capacity of primary 
hMPCs, we compared markers of expansion between young and old, male and female primary 
hMPC cultures. hMPCs from older males have reduced expansion capacity compared to their 
younger counterparts, but hMPCs from females are largely unaffected by age. Proliferating 
MPCs have high energetic and biosynthetic material requirements, and the ability to utilize 
oxidative phosphorylation (OXPHOS) and/or glycolysis may affect the expansion capacity of 
MPCs. Results from our study suggest that reduced expansion capacity in OM-hMPCs is 
accompanied by alterations in measurements of OXPHOS while glycolysis is maintained. 
  
However, we and others have demonstrated that not all old hMPCs have impaired expansion 
capacity and similarly, not all young hMPCs expand better than old hMPCs.  
Using K-means cluster analysis and measurements of culture population doubling time 
and saturation density, we are the first to unbiasedly cluster cultures with similar growth 
parameters and to identify drivers of expansion capacity that weren’t related to categorical age or 
sex. Our primary findings demonstrate that cultures with enhanced expansion capacity have 
DEgenes enriched in functional classifications, pathways and networks that suggest promotion of 
the cell cycle, reduced apoptosis and cellular senescence, and enhanced DNA replication.  
Acute inflammation following muscle injury is essential to activate satellite cells. 
However, chronic muscle inflammation likely contributes to impaired regenerative capacity in 
skeletal muscle. Previous research has identified muscle inflammatory susceptibility, or the 
ability to manage and respond to inflammation, as a predictor of failed muscle regeneration and 
regrowth following surgery. We determined a transcript profile that distinguishes human muscle 
progenitor cell (hMPC) cultures with high and low inflammatory susceptibility. DEgene 
enrichment suggested that MuIS+ cells had promotion of inflammatory pathways and inhibition 
of muscle differentiation pathways. Novel (KISS1) and known (SMARCA4, MYOD1, IL1β) 
genes emerged as regulators for identified functional pathways. When compared to other 
transcriptomics datasets, MuIS+ cultures share overlap in transcript profiles to both individuals 
who do not respond to progressive resistance exercise training and to older adults with 
diminished muscle strength. 
This dissertation highlights the heterogeneity that exists between humans throughout the 
muscle regenerative process. Uncovering the molecular underpinnings of this heterogeneity is 
essential as the field of medicine moves towards a personalized approach.  
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CHAPTER 1. REVIEW OF LITERATURE 
 
1.1 Skeletal muscle function and structure  
Skeletal muscle (SkM) is the largest organ system in the body (132). Functionally, the 
skeletal muscle is best known for its roles in maintaining posture, producing movement, and 
protecting bones and joints. Additionally, the SkM plays important roles in metabolism. The 
SkM acts as a secretory organ; it releases cytokines (“myokines”) that have autocrine, paracrine, 
and endocrine effects (132). The SkM is the largest glucose sink in the body accounting for 
~75% of insulin-stimulated glucose uptake, it stores carbohydrate in the form of glycogen (17), 
and it contains 50-75% of all body proteins (59).  
Structurally, the SkM is composed of multinucleated, post mitotic muscle cells 
(myofibers) that are formed by the differentiation and fusion of myoblasts in a process known as 
myogenesis. The myofibers are surrounded by a cell membrane or sarcolemma. Myofibers are 
bundled into muscle fascicles and surrounded by the perimysium, another layer of connective 
tissue. The entire muscle is surrounded by a third layer of connective tissue called the 
epimysium. The size of a muscle is determined largely by the number and size of the individual 
myofibers; however, infiltrating fat and connective tissue can also alter the size of the muscle 
(56, 81). The structural composition of SkM is shown in Figure 1.  
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Figure 1. Skeletal Muscle Structure (photo taken from Pearson Education © 2013) 
 
1.2. Skeletal muscle regeneration  
Over a lifetime, skeletal muscle may be injured in various ways including burns, wounds, 
surgical trauma, and exercise injuries. Importantly, subtle myofiber injuries routinely occur 
secondary to regular activities (39). Adequate repair and regeneration following damage are 
necessary to maintain muscle structure, function, and metabolic homeostasis throughout the 
lifespan (170). When the SkM is injured, satellite cells [(SC), the adult stem cells found in the 
skeletal muscle] are activated to repair the damaged tissue. SCs are located between the 
sarcolemma and the basal lamina in a quiescent state until activated by stimulating factors. Once 
activated, SCs proliferate, differentiate, and fuse with other myogenic cells or with existing 
myofibers to repair and/or regenerate injured tissue (Figure 2). When damage is subtle, SCs or 
their progeny fuse with existing myofibers; however, when damage is severe, SCs or their 
progeny fuse with each other to form new myofibers (73, 76).  
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Figure 2. Changes in Myogenic Regulatory Factors and Metabolism throughout Muscle 
Regeneration 
 
SCs express PAX7, an essential transcription factor for regulating myogenic potential, or 
the potential of cells to progress through the major phases of SkM formation. In vivo, Pax7-/- 
mice have a complete absence of SCs in SkM (160), and muscles in Pax7-/- mice are reduced in 
size and contain 50% the normal number of nuclei (127, 142, 160). Deletion of Pax7+ cells in 
vivo also results in impaired regeneration, marked by reduced formation of myotubes and 
increased deposition of fibrotic tissue (19, 94). In the absence of injury, Pax7+ cells also fuse 
with existing myotubes and contribute to the homeostatic maintenance of SkM over time, 
especially in aged muscle (174). In vitro, deletion of Pax7 in primary myoblasts inhibits 
proliferation and results in complete growth arrest (180). Thus, Pax7+ SCs are essential for both 
homeostatic maintenance and regeneration of SkM. 
Upon injury, Pax7+ cells are activated by stimulating factors [e.g. fibroblast growth 
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factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), interleukin-6 
(IL6), or tumor necrosis factor-alpha (TNFα)]. Once activated, SCs express the transcription 
factors MYF5 and MYOD and proliferate. MPCs progress through proliferation, and committed 
MPCs differentiate, exit the cell cycle, and fuse to form myotubes that repair injured muscle. 
Adequate expansion of the MPC population is essential for muscle regeneration. It is postulated 
that expansion of the MPC population promotes the formation of myotubes with greater numbers 
of nuclei and larger mass (99). In vivo, inhibiting expansion of the MPC population via radiation-
induced damage (140) or pharmacological inhibition (151) prevents muscle regeneration.  
Following expansion, a subset of cells differentiate into mature myofibers. MPCs that 
enter differentiation express the transcription factors myogenin (MYOG), a master regulator of 
the differentiation process, and MRF4. In vivo, a subset of SCs do not proceed to differentiation 
but instead reinstate the quiescent state and self-renew the SC pool (5). In summary, successful 
SkM regeneration requires this well-orchestrated series of events from activation of the quiescent 
SC, to expansion and differentiation of the committed myoblast or MPC, and formation of 
multinucleated cells.  
 
1.3 Age and skeletal muscle regenerative capacity  
Life-expectancy from birth and from the age of 60 years continues to increase; the 
average life-expectancy in the United States is 78.8 years and 83.2 years for men and women, 
respectively, an approximate 16 year increase since 1940 (24). However, in 2010, over 25% of 
those aged ≥ 65 years reported difficulty walking and climbing stairs, while 18.5% reported 
difficulty conducting errands independently (187). In healthy, young men and women, SkM 
accounts for approximately 42% and 34% of human body weight, respectively (80). However, 
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this percentage declines with age to SkM accounting for 36% and 30% of human body weight in 
70+ year old men and women, respectively (80). The overall reduction in the size of SkM is 
accompanied by an increase in fat infiltration with age, independent of sex (43), and a decline in 
power, strength and endurance (54, 157). Over time, the decline in the structural and functional 
properties of SkM results in physical disability and loss of mobility and independence, especially 
in the elderly (9, 46, 138). Thus, although human life-expectancy is increasing, older adults and 
adults with chronic disease may face a larger window of diminished quality of life.   
Loss of SkM is accompanied by a decrease in the size and number of myofibers (50, 91). 
A decrease in the number of myonuclei has also been reported in aged muscle (18). A myonuclei 
can only support a certain volume of cytoplasm, and changes in myofiber cross-sectional area are 
paralleled by changes in the number of myonuclei (197). Since SCs donate their nuclei to 
myofibers, a decline in the number of SCs with age could be one mechanism explaining the 
decrease in the number of myonuclei with age. However, studies comparing the numbers of SCs 
in aged muscle have reported varying results, likely due to differences in the species studied and 
the methods used (e.g. immunohistochemistry versus fluorescence activated cell sorting). Several 
studies have reported a decrease in SC number with age (20, 156, 161, 164), while others report 
no change (35). Most likely, altered regenerative potential in aged muscle is a result of changes 
in both SC number and SC function with age.  
Loss of the ability to return to quiescence and to self-renew with age may be one 
mechanism through which SC number and function decrease with age. If aged SCs lose their 
intrinsic capacity to self-renew, the SC pool shrinks. p38α/β signaling is involved in SC 
activation, and p38α/β is overstimulated in aged SCs (16). Over-activation of the p38α/β 
pathway induces SC activation and reduces self-renewal. Activation of the p38α/β pathway is not 
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altered when old SCs are transplanted into a young niche (16, 36), suggesting over-activation of 
the p38 pathway may be an intrinsic defect in aged SCs. Additionally, Cosgrove et al. reported 
that two thirds of aged SCs fail to successfully transplant even when placed into a young mouse 
(36), further supporting the presence of intrinsic defects in aged SCs.  
Following injury or transplantation, activated SCs must proliferate to generate sufficient 
cell numbers to fuse or repair damaged tissue. However, SCs from aged mice have higher rates 
of apoptosis and senescence when cultured; thus, expansion of the SC population from aged 
mice is impaired (34). In aged animals, SC activation is delayed and proliferation is impaired, 
resulting in fewer cells available to fuse with injured tissue (13). Additionally, following injury 
in vivo, fewer myoblasts are generated in myofiber explant cultures from aged compared to 
young or adult mice (35). In rats, muscle regeneration following injury is prolonged (3 weeks in 
old versus 1 week in young), and myofibers formed are smaller in size (155). Thus, although the 
reasons for impaired regeneration with age are multi-factorial, impairments in MPC expansion 
capacity are an important factor affecting the success of aged SkM regeneration and 
transplantation. Despite evidence in mouse and rat models, data on human MPCs (hMPCs) and 
the effect of chronological age on hMPC expansion capacity remains limited.  
 
1.4 Sex and skeletal muscle regenerative capacity 
Sex differences in SkM health have been reported throughout the lifespan. On average, 
males have greater SkM mass and larger muscle cross-sectional area compared to females (114, 
152). Transcriptomics has been used to understand baseline differences in the size of male and 
female SkM from healthy adults (aged 20-75 years). In total, over 3,000 genes were reported as 
differentially expressed (DEgenes) between male and female SkM (185). However, only a few of 
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the DEgenes were obvious candidates for explaining the sex-related difference in SkM mass 
(185). For example, differences in IGF1 and GDF8 (myostatin) expression could contribute to 
the sex difference in muscle size (185).     
At the whole tissue level, sex-related SkM differences in function with age are mixed. 
Studies report that males lose SkM mass at a faster rate with age than females (195). 
Additionally, males lose almost twice the strength that females lose with age (69). However, 
other reports suggest that females have an increased probability of encountering age-related 
functional disability (79), a greater likelihood of experiencing frailty (118), and a greater chance 
of developing metabolic disease (141). While sex-related differences in SkM are present 
throughout the lifespan, it is not obvious why differences in measures of functional outcomes 
occur.  
At the cellular level, male and female SCs have comparable contributions to muscle 
regeneration after transplantation in mice (122). However, 3 month and 1 year old male mice 
have more SCs per myofiber than age-matched female mice, suggesting that male mice have a 
greater pool of SCs (122). Additionally, Manzano et al. reported that SCs isolated from 40, 60, 
and 120 day old male mice have higher proliferation rates compared to SCs isolated from female 
mice (108). With age, the reduction in SCs per myofiber is more prominent in female mice 
compared to male mice (39). Although evidence from animal models suggest sex-specific 
differences in the MPC population, data comparing male and female hMPCs remains limited.  
 
1.5 Metabolism and muscle regenerative capacity  
Throughout the lifespan, metabolism of macronutrients provides substrates and energy 
necessary to regenerate injured muscle and to maintain muscle mass. Inadequate energy and/or 
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protein intake results in loss of lean body mass and can lead to increased injury risk (130, 131). 
At the cellular level, the metabolism of macronutrients plays an important role in the control of 
SC stemness and in the expansion and differentiation of activated SCs (65). A simplified 
schematic of macronutrient metabolism is shown in Figure 3 (153). Our current understanding 
of glycolytic and oxidative phosphorylation (OXPHOS), throughout myogenesis/ the 
regenerative process, is shown in Figure 2. Glucose is metabolized, in the cytoplasm, to pyruvate 
through glycolysis, a process that does not require oxygen. Although each round of anaerobic 
glycolysis only produces two net molecules of ATP, glycolysis also produces essential 
biosynthetic building blocks; byproducts of glycolysis are necessary for nucleotide, lipid, and 
amino acid biosynthesis (Figure 3). Pyruvate, the glycolytic end product, can either be converted 
to lactate in the cytoplasm or shuttled into the mitochondria and converted to acetyl CoA for 
OXPHOS. Additionally, pyruvate can be converted to oxaloacetate, a TCA cycle intermediate, 
by pyruvate carboxylase in an anaplerotic reaction. The metabolism of fatty acids and amino 
acids can also produce acetyl CoA for OXPHOS. OXPHOS generates large amounts of ATP (up 
to 36 ATP molecules).   
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Figure 3. Macronutrient Metabolism Pathways. Taken from Ryall et. al, 2013 
 
Quiescent SCs reside in a state of little or no basal cellular turnover and have very low 
energy needs (42). Quiescent SCs co-localize with capillaries and nerves, which suggests an 
aerobic niche (65). Compared to activated SCs, quiescent SCs have an enrichment of genes that 
regulate lipid transport (62). It is postulated that unlike other stem cells, quiescent SCs may 
primarily oxidize fatty acids through OXPHOS (65). Because oxidative stress occurs secondary 
to OXPHOS, long-lived SCs need a mechanism to protect against oxidative damage (65). SCs 
respond to oxidative stress by removing damaged mitochondria via autophagy (the controlled 
degradation and recycling of cellular components) (186); autophagy is essential to maintain the 
stem-cell quiescent state in mice (63). Compared to quiescent SCs, proliferating murine 
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myoblasts [C2C12 and mouse primary MPCs (mMPCs)] have higher metabolic rates and greater 
lactate production (93, 154). mMPCs, during early proliferation (3 and 24 h after plating), also 
have greater extracellular acidification rates (ECAR, a measure of glycolysis) and greater 
expression of genes involved in glycolysis compared to freshly isolated SCs (154). Furthermore, 
Ryall et al. demonstrated that SCs transition from utilizing primarily fatty acid oxidation to 
utilizing primarily glycolysis during the switch from quiescent to proliferating SCs (154). 
Although glycolysis is inefficient for energy generation compared to OXPHOS, use of glycolysis 
allows cells to generate essential biosynthetic materials and to respond quickly to energy 
demands (104). Cellular metabolism is reprogrammed from OXPHOS to glycolysis during 
activation. Evidence suggests the enzymatic activity of sirtuin 1 (SIRT1) plays a role in this 
reprogramming (154). SIRT1 has also been shown to regulate autophagy during activation; 
autophagic flux is induced during activation and inhibition of autophagic flux delays SC 
activation (167). Increased autophagy during activation provides substrates for ATP generation 
to meet the increased energy needs of activation (167).  
As expansion proceeds, proliferating mMPCs significantly increase mitochondrial 
content and the expression of genes associated with the TCA cycle (154). Thus, while glycolysis 
plays a role in MPC activation, MPCs may rely more on OXPHOS as expansion continues. 
OXPHOS is essential for differentiation; inhibiting the assembly of the electron transport chain 
inhibits myotube formation (146). Differentiated cells do not need to sustain high rates of 
replication and therefore have a lower anabolic demand. However, they do require significant 
energy to support homeostasis and muscle contraction; it is well accepted that fully differentiated 
myotubes rely heavily on OXPHOS to meet their high metabolic needs (93, 181). Thus, both 
glycolysis and OXPHOS are important for varying stages of MPC expansion, differentiation, and 
 11 
fusion into mature multinucleated cells.  
 Impairments in metabolism may underlie poor muscle regeneration by limiting the 
substrates or energy necessary to complete cellular processes of regeneration. Aged SkM has 
reduced energy, glucose, protein, and fat metabolism (68). Genes related to mitochondrial 
function and the TCA cycle are also reduced in SkM from older adults when compared to 
younger adults, with the lowest expression levels in frail older adults (51). Expression of genes 
related to mitochondrial function including peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1α) target genes are also reduced in older adults when compared to 
younger adults (51); PGC1α is a transcription factor that promotes mitochondrial biogenesis. At 
the cellular level, replicative aging (continuing to passage cells until senescence) reduces whole 
cell ATP production (116). Aging via replication has been shown to alter glycolytic enzymes 
(12), downregulate OXPHOS (128), and decrease glucose uptake, glycogen synthesis, and fatty 
acid oxidation (123). However, despite evidence in whole tissue and in hMPCs aged via 
replication, the effect of chronological or biological age on metabolism in hMPCs remains 
unknown.   
 
1.6 Inflammation and skeletal muscle regeneration 
 Inflammation plays a key role in muscle regeneration. Upon injury, the body initiates an 
acute phase inflammatory response characterized by upregulation of the pro-inflammatory 
cytokines interleukin 1β (IL-1β) and tumor necrosis factor alpha (TNFα) (107, 172). These 
cytokines can be released by both resident macrophages or by the muscle itself and act through 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) to upregulate expression 
of additional pro-inflammatory genes (Figure 4) (132, 172). These cytokines also act as 
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chemoattractants to attract additional macrophages from the circulation and increase proteolysis 
of the injured muscle (139). Attracted macrophages release growth factors that promote muscle 
repair through promoting SC proliferation (145). TNFα itself also activates SCs and promotes 
the transition from G1 to S phase of the cell cycle (95).  
 
Figure 4. Inflammatory Cytokine Signaling 
 
Although an acute inflammatory response is essential for muscle repair, chronic 
inflammation can result in myopathies including muscle wasting and tissue remodeling (89). 
Infusion of IL-1β or TNFα inhibits muscle protein synthesis and induces skeletal muscle 
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catabolism in rats (98). Looking downstream of IL-1β or TNFα, NF-κB increases the expression 
of murine ring finger-1 (MuRF1), a critical mediator of muscle atrophy (22). TNFα also inhibits 
myoblast differentiation and fusion by post-transcriptionally repressing MYOD (74, 115). 
Inhibiting NF-κB in vivo or in vitro improves proliferation and myogenic differentiation (102). 
The effects of chronic inflammatory cytokine exposure promote protein degradation and inhibit 
successful muscle regeneration.  
 Higher baseline levels of muscle inflammation and higher proinflammatory signaling in 
response to damage [termed muscle inflammatory susceptibility (MuIS+)] have been associated 
with impaired differentiation and fusion in hMPCs from older human adults (112). In a follow-
up study, those with MuIS+ also experienced lower rates of muscle protein synthesis following 
surgery (10). Thus, localized MuIS+ may be a contributing factor to long-term disability in some 
individuals following trauma or surgical procedures. However, why some individuals develop 
MuIS+ while others do not is not understood. An –omics based approach may provide insight 
into the molecular underpinnings of the MuIS+ phenotype.  
 
1.7 Transcriptomics  
 High-throughput sequencing methods, such as RNA-sequencing (RNAseq), can be used 
to comprehensively measure changes in an organism’s transcriptome (the sum of all its 
transcripts) with time, cell type, or condition. Genetic information is carried on DNA. This 
information is transcribed and carried by mRNA. RNAseq generates cDNA sequences derived 
from all RNA molecules in a sample. These cDNA sequences are then constructed into a library 
and sequenced using massive parallel deep sequencing technologies. Expression level of mRNA 
targets can be quantified in an unbiased way with high resolution (single base pair resolution) 
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(183). This process is outlined in Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Overview of Typical RNAseq Pipeline 
 
 RNAseq can be used to determine genes that are differentially expressed (DEgenes) 
between samples, time-points, or conditions. Fragments Per Kilobase of transcript per Million 
mapped reads (FPKM) values are determined for each gene within a sample. These FPKM 
values account for the number of fragment reads with respect to the overall mapped read number 
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and the gene length. FPKM values are then compared and the significance and the fold change 
differences between groups are determined.  
While lists of DEgenes are informative, DEgene lists may overlook important biological 
changes. Minor changes in multiple genes in a pathway may have large biological consequences 
but may be overlooked by DEgene comparisons alone. Pathway analysis is a powerful tool that 
connects expression changes to the function of individual genes and the roles of these genes in 
biological pathways. Analyses of differentially expressed biological pathways often provide 
more insight than lists of seemingly unrelated DEgenes (137). Programs such as Ingenuity 
Pathway Analysis (IPA) develop outputs identifying top canonical pathways, functional 
categories, and networks of DEgenes between conditions. Based on the directional changes of 
DEgenes (i.e. up- or down-regulated), the directionality of the identified pathway, category, or 
network can be predicted. IPA also predicts upstream regulators that may control the DEgenes 
and alter biological functions of interest. In this way, RNAseq can be used as an exploratory tool 
to generate hypotheses about upstream regulators controlling DEgene expression. Although 
RNAseq and pathway analysis can be useful in hypothesis generation, it is important to 
remember that this tool only provides information at the level of transcription. Changes at the 
mRNA level do not always translate into changes in the level of functional proteins.  
 
1.8 Benefits and limitations of the model 
 Use of a cell culture model for understanding human SkM regeneration has important 
benefits and limitations. hMPC populations largely retain the donor metabolic phenotype and 
have the most relevant genetic background to address age- and sex-related differences in MPC 
expansion capacity and metabolism (1). However, our model is also limited by the use of 
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isolated satellite cells; the tissue niche has been shown to play a critical role in the muscle 
regeneration process (193). It is unlikely that impaired muscle regeneration is solely a function 
of alterations in SCs. Rather, it is a combination of intrinsic changes within SCs and extrinsic 
changes within the tissue niche that alter regenerative capacity. Additionally, a potential 
limitation of our research model is use of passage six hMPCs. It is recognized that proliferative 
capacity declines with passaging (106).  
  
1.9 Summary 
 Animal models have been widely used to investigate the effects of age, sex, and 
inflammation on different stages of SkM regeneration. However, hMPCs largely retain the donor 
metabolic phenotype and have the most relevant genetic background to address questions related 
to human variance in muscle regeneration (1). Upon critical evaluation of the literature, it is 
apparent that to better understand how human heterogeneity impacts muscle regeneration, 
whether based on categorical variables such as age or sex or phenotypic variables such as growth 
speed or inflammatory susceptibility, studies using human primary cultures need to be 
conducted. The results of these experiments are presented in Chapters 2, 3, and 4.  
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CHAPTER 2: EXPANSION CAPACITY OF HUMAN MUSCLE PROGENITOR CELLS DIFFERS BY 
AGE, SEX, AND METABOLIC FUEL PREFERENCE 
 
 
Emily S Riddle, Erica L Bender, Anna E Thalacker-Mercer 
 
Author Affiliations: Division of Nutritional Sciences, Cornell University, Ithaca, NY, 14853, 
USA (ER, HR, EB, ATM) 
 
Abbreviated Title for Running Head: Muscle Progenitor Cell Growth and Metabolism 
 
Corresponding Author: Dr. Anna Thalacker-Mercer, aet74@cornell.edu, 109 Savage Hall, 
Cornell University, Ithaca, NY 14850 
 
Emily S Riddle: Experimental design, data collection, data analysis, and interpretation  
Erica L Bender: Data collection 
Anna E Thalacker-Mercer: Experimental design, data collection, data analysis, and interpretation 
 
Keywords: Muscle progenitor cells, metabolism, cell proliferation, sex differences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
2.1 Abstract 
 
Activation of satellite cells and expansion of the muscle progenitor cell (MPC) 
population is essential to generate a sufficient number of cells to repair damaged skeletal muscle 
(SkM). Proliferating MPCs have high energetic and biosynthetic material requirements, and the 
ability to utilize oxidative phosphorylation (OXPHOS) and/or glycolysis may affect expansion 
capacity of MPCs. In the present study, we investigated the effect of donor age and sex on 
human MPC (hMPCs) expansion capacity and metabolic fuel preference. hMPCs from young 
and old males and females were grown for 408 h (17 days). Percent confluency, live nuclei 
count, and dead cell count were measured every 24 h. Metabolic phenotype was assessed using 
glucose uptake, expression of genes related to glycolysis and OXPHOS, and the Seahorse XF24 
Phenotype Test Kit during the exponential phase of growth. hMPCs from old male donors had 
impaired expansion capacity secondary to heightened cell death early in expansion compared to 
hMPCs from young male donors, an effect not observed in female hMPCs. Age-related 
differences in metabolism were also sex-dependent; markers of OXPHOS were altered in old (vs. 
young) male hMPCs while markers of metabolism were largely unaffected by age in female 
hMPCs. For the first time, we identify sex-specific differences in cell death and OXPHOS that 
contribute to impaired expansion capacity of hMPC cell populations with age. 
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2.2 Introduction 
 
The regenerative process following skeletal muscle (SkM) damage is necessary to 
maintain SkM composition and function throughout the lifespan. Impaired SkM regeneration 
post injury is related to pathological tissue remodeling and deterioration of the muscle with age 
(60). Successful regeneration requires a well-orchestrated series of events including activation of 
quiescent, SkM specific stem cells [satellite cells (SCs)] followed by proliferation and 
differentiation of committed myoblasts [muscle progenitor cells (MPCs)], and formation/repair 
of functional multinucleated muscle cells (29). Activation of SCs and expansion of MPCs is 
essential to generate a sufficient number of viable cells to repair damaged SkM (4). In vitro, 
MPC expansion encompasses cell division and cell death, as well as the ability of cells to reach 
confluence. Greater expansion of MPCs is postulated to promote the formation of myotubes with 
higher numbers of nuclei and increased mass (99); inhibiting expansion of the MPC population 
via radiation-induced damage (140) or pharmacological inhibition (151) prevents muscle 
regeneration.  
Throughout MPC expansion, catabolism of macronutrients provides the substrates and 
energy needed to support the generation of new cells and cellular structures (153). Although 
glycolysis is inefficient for energy generation compared to oxidative phosphorylation 
(OXPHOS), use of glycolysis allows cells to generate essential biosynthetic materials and to 
respond quickly to energy demands (104). Compared to quiescent and differentiating cells, 
proliferating murine myoblasts [C2C12 cells and mouse primary MPCs (mMPCs)] have higher 
metabolic rates and higher lactate production (93, 154). mMPCs during early proliferation (3 and 
24 h after plating) also have greater extracellular acidification rates (ECAR, a measure of 
glycolysis) and greater gene expression of enzymes involved in glucose catabolism compared to 
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freshly isolated SCs (154). Later in expansion (48 h after plating), proliferating mMPCs 
significantly increase mitochondrial content and the expression of genes associated with the TCA 
cycle (154). Thus, both glycolysis and OXPHOS appear to be important throughout myoblast 
expansion.  
In animal models, age is associated with reduced MPC expansion capacity in vitro (28, 
34). MPCs derived from young rats attain more population doublings compared to MPCs derived 
from old rats (28). Similarly, human MPCs (hMPCs) “aged” via replication have longer 
population doubling times compared to their “younger” counterparts that have undergone fewer 
replications (123). Evidence also suggests that sex may impact MPC expansion capacity; 
throughout the lifespan in mice, male mMPCs exhibit higher proliferation rates than female 
mMPCs (108). Although the effects of chronological age and sex on expansion of MPCs from 
animals are accepted, the effects of chronological age and sex on expansion of hMPCs remains 
unknown. Furthermore, although studies have compared the metabolism of proliferating cells to 
the metabolism of quiescent or differentiating cells, no studies to date have determined the 
effects of chronological age and sex on hMPC metabolic fuel preference throughout expansion. 
Therefore, the aim of the present study was to determine the effect of age and sex on expansion 
capacity and metabolism in hMPCs.  
 
2.3 Methods 
 
2.3.1 Ethical approval 
All studies were approved by the Cornell University, Institutional Review Board. Written 
informed consent was obtained from all participants. 
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2.3.2 Human donors  
Human MPCs from healthy, ambulant young and old, males and females were used to 
address the objectives of this research. Average weight, BMI, and age of participants in each 
group are presented in Table 1. There were no significant differences in weight between young 
and old participants within sex, and there were no significant differences in BMI between any of 
the groups. All individuals completed a comprehensive health history and physical activity 
questionnaire and were independently ambulatory and cognitively intact (as determined by the 
examining nurse practitioner). All individuals were relatively active; individuals in all age-by-
sex groups participated in endurance and/or resistance exercise ≥ 2 days per week. All subjects 
were requested to refrain from exercise within 24 h of the biopsy. Individuals were excluded for 
contagious infections and any chronic end-stage disease expected to limit life-expectancy to less 
than one year, induce anorexia, or restrict physical activity. Individuals with seated resting 
systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg and individuals 
receiving anabolic (e.g., GH, IGF-I) therapy were also excluded.  
 
Table 1. Subject Characteristics 
Group Number in 
Group 
Average 
Weight (kg) 
Average BMI 
(kg/m2) 
Average Age 
(y) 
Young Males 
(YM-hMPCs) 
6 80.2 ± 16.6 25.3 ± 4.2 28.5 ± 7.1 
Old Males  
(OM-hMPCs) 
3 78.3 ± 8.9 27.9 ± 4.3 72.0 ± 7.0 
Young Females 
(YF-hMPCs) 
6 64.2 ± 12.0 24.2 ± 6.0 30.0 ± 5.7 
Old Females 
(OF-hMPCs) 
6 65.0 ± 7.5 24.3 ± 4.0 70.8 ± 6.9 
Data are presented as mean +/- SD. 
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2.3.3 Purified, primary human muscle progenitor cells 
Primary human SCs were obtained from the vastus lateralis muscle using the 
percutaneous biopsy technique. The biopsy tissue was cleaned of any extraneous fascia and 
adipose tissues. Approximately 75-100 mg of the total muscle biopsy was stored in Gibco® 
Hibernate®A (Thermo Fisher Scientific) at 4°C until tissue disassociation was performed. After 
mincing and washing via gravity with Ca-Mg free D-PBS, the tissue was disassociated in digest 
medium [2mg/mL Collagenase D (Roche) in low-glucose DMEM]. After 30 minutes in digest 
medium, fresh digest medium and Dispase (Sigma) were added. The disassociating pellet was 
titurated until a uniform slurry was achieved. Growth medium [(GM) Hams F12 + 20% FBS + 
5ng/mL bFGF (Promega) + 1% Pen/Strep (Gibco)] was added to the slurry and passed through a 
70 μm cell strainer into a sterile tube. The cell suspension was centrifuged. The pellet was 
resuspended in Recovery® freezing medium (Gibco) and cryopreserved at -80°C. Thawed cells 
were seeded on a type-I collagen coated culture dish (initial cell confluency ~15%). After 24 h, 
the GM was replaced with fresh GM and further replenished every 48 h. Once cells reached 
~70% confluency, they were removed from the plate using 0.05% trypsin and passaged. Cells 
were expanded to passage four, then cryopreserved in 10% DMSO + GM.  
  
2.3.4 Fluorescence activated cell sorting 
Approximately 1-1.5 million cells were labeled with fluorescently-conjugated antibodies 
specific for myoblast cell surface antigens CD56 (NCAM; PE-Cy7-conjugated) and CD29 (β1-
integrin; AlexaFluor488-conjugated) and the viability stain 7-Aminoactinomycin D (7AAD) 
(191). Individual samples yield 150,000 – 800,000 viable CD56+/CD29+ hMPCs per 1 million 
cells sorted using a BD FACS Aria™ Fusion flow cytometer. Sorted CD56+/CD29+ cells (>98% 
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positive) were expanded in culture by passaging twice and then used in experiments; all in vitro 
experiments were performed using sorted cells at passage six. Due to high rates of cell death, 
only three old male cultures yielded a sufficient number of cells to be sorted and used in 
experiments.    
 
2.3.5 Growth curves 
Sorted hMPCs were seeded at a density of approximately 10% (~2000 cells) and 
proliferated in GM for 408 h (17 days) in 96 well plates. GM was changed every 48 h. Live cell 
count, percent dead, and percent confluency in each culture were measured every 24 h after 
seeding using the Celigo® S Imaging Cytometer (Nexcelom Bioscience). Use of the Celigo® S 
enabled the imaging of all cells in each well with little disruption to the culture. Confluency was 
measured using a minimum of 2 wells per day (confluency of 2-9 wells was averaged per day) 
with the exception of the final day of growth, in which only one well was measured. To validate 
growth curve measurements, on a separate day, growth curves were generated in duplicate for a 
subset of samples; no differences in growth curves were observed between separate day, 
duplicated growth curves [(n=7), data not shown]. Live cells were measured every 24 h by co-
staining cells with Hoescht 33342 (to identify nuclei) and fluorescently labeled propidium iodide 
(to identify dead cells). Propidium iodide positive cells were subtracted from Hoescht 33342 
positive cells to determine the total number of live cells. The number of propidium iodide 
positive cells were divided by the number of Hoescht 33342 positive cells to determine the 
percentage of dead cells. Using live nuclei counts, percent dead, and percent confluency, we 
determined live nuclei net area under the curve (nAUC), percent dead, total area under the curve 
(tAUC), confluency nAUC, population doubling time [duration*log(2)/log(final concentration) – 
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log(initial concentration)], and saturation density (the number of live nuclei at growth plateau 
divided by area of the well) for each culture.  
 
2.3.6 RNAseq 
An existing RNAseq database was leveraged to support observed differences in 
expansion phenotype. Importantly, the questions we asked and the analyses we used were 
completely different from our previous use of this RNAseq dataset (143). Briefly, TruSeq-
barcoded RNAseq libraries were generated with the NEBNext Ultra II RNA Library Prep Kit 
(New England Biolabs). Each library was quantified with a Qubit 2.0 (dsDNA HS kit; Thermo 
Fisher) and the size distribution was determined with a Fragment Analyzer (Advanced 
Analytical) prior to pooling. Libraries were sequenced on a NextSeq500 instrument (Illumina). 
At least 20M single-end 75 bp reads were generated per library. Reads were trimmed for low 
quality and adaptor sequences with cutadapt v1.8 (parameters: parameters: -m 50 -q 20 -a 
AGATCGGAAGAGCACACGTCTGAACTCCAG --match-read-wildcards) (109). Reads were 
mapped to the reference genome/ transcriptome using tophat v2.1 (parameters: --library-type=fr-
firststrand --no-novel-juncs -G <ref_genes.gtf>) (85). Cufflinks v2.2 (cuffnorm/cuffdiff) was 
used to generate the fragments per kilobase of transcript per million mapped reads (FPKM) 
values and statistical analysis of differentially expressed genes (DEgenes) (176). Ingenuity 
Pathway Analysis (IPA) was used to identify canonical pathways and molecular and cellular 
functions of DEgenes. The software was set to analyze transcripts with an FDR corrected q value 
≤ 0.01.  
 
2.3.7 Seahorse flux analysis 
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The Seahorse XF24 Flux Analyzer and the Seahorse Phenotype Test Kit (Agilent) were 
used, following manufacturer’s instructions, to measure the baseline metabolic phenotype, the 
stressed metabolic phenotype, and the metabolic potential of the hMPC cultures during 
expansion. Metabolic phenotype was characterized by the extracellular acidification rate 
[(ECAR), a proxy measure of glycolysis] and the oxygen consumption rate [(OCR), a proxy 
measure of OXPHOS] of each culture. Cells were seeded at 17,000 cells per well in phenol red 
free DMEM (10 mM glucose, 2 mM glutamine, 1 mM pyruvate) with 10% FBS and grown for 
72 h (media was changed at 24 h). After 72 h, media was changed to bicarbonate free phenol red 
free DMEM (10 mM glucose, 2 mM glutamine, 1 mM pyruvate). After the baseline metabolic 
phenotype (OCR and ECAR) was measured, 1μM of each of the stress inducing compounds, 
oligomycin which maximizes glycolysis and carbonylcyanide-4-(trifluoromethoxy)-
phenylhydrazone (FCCP) which maximizes OXPHOS, were injected simultaneously into each 
well to induce an energy demand. After injection of the stress inducing compounds, OCR and 
ECAR were measured again (stressed OCR and stressed ECAR) to determine the stressed 
metabolic phenotype. The metabolic potentials for OXPHOS and glycolysis were calculated 
using the ratio of stressed OCR/baseline OCR and stressed ECAR/baseline ECAR, respectively. 
Metabolic potential (the percent change from baseline to stressed after the addition of stressor 
compounds) is presented as % baseline. Each sample was run in triplicate. OCR and ECAR 
values were normalized by the number of live cells in the well. After Seahorse measurements 
were obtained, Hoescht 33342 and propidium iodide were used to stain for the number of total 
nuclei and dead nuclei, respectively. Propidium iodide positive cells were subtracted from total 
nuclei to determine the number of live cells in each well. All Seahorse measurements were run in 
triplicate and normalized to the number of live cells in each well.  
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2.3.8 Gene expression in early proliferation 
RNA was harvested from sorted cells using TRK lysis buffer (Omega) following 
manufacturer’s instructions at the first day and third day of rapid expansion. The first day of 
rapid expansion was defined as the first increase in percent confluency of ≥ 5%. Confluency in 
OM-hMPCs never increased by ≥ 5% in a 24 h interval. Thus, after 72 and 120 h of growth, 
RNA from OM-hMPCs was harvested. An EZNA total RNA kit (Omega) was used for total 
RNA extraction following the manufacturer’s instructions. Total RNA quantity and quality was 
determined spectrophotometrically, followed by cDNA synthesis using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). We analyzed key targets related to glucose 
uptake and metabolism, fatty acid transport and metabolism, and mitochondrial biogenesis. We 
used real-time, quantitative PCR performed using the LightCycler 480 system (Roche) with the 
TaqMan Fast Advanced Master Mix and TaqMan® Gene Expression Assays (Applied 
Biosystems) to identify differences in gene expression of select genes. Assays were used to 
quantify mRNA levels of glucose transporters [GLUT1 (Hs00892681_a1), GLUT4 
(Hs00168966_m1)], a fatty acid transporter [CD36 (Hs00169627_m1)], and a marker of 
mitochondrial biogenesis [PPARGC1 (Hs01016719_m1)]. TBP (Hs00427621_m1) was used as 
the housekeeper. Each PCR reaction was run in triplicate.  
  
2.3.9 Glucose uptake  
The Glucose Uptake-Glo Assay (Promega) was used following manufacturer’s 
instructions to quantify glucose uptake in proliferating cells. Briefly, cells were seeded at 17,000 
cells per well in phenol red free DMEM (10 mM glucose, 2 mM glutamine, 1 mM pyruvate) and 
grown for 72 h (media was changed after 24 h). After 72 h of growth, medium was removed and 
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cells were washed with glucose free media. Media was replaced with 1mM diluted 2-
deoxyglucose (diluted in glucose and phenol red free DMEM). Cells were incubated in 2-
deoxyglucose for 1 h, before the addition of stop buffer, neutralization buffer, and 2-
deoxyglucose-6-phosphate (2DG6P) detection reagent. Cells were incubated in 2DG6P detection 
reagent for 1 h at room temperature, and luminescence was measured using a microplate reader. 
Luminescence was normalized to total cell number in each well, determined using Hoescht 
33342. All samples were run in duplicate.  
 
2.3.10 Statistics 
 Two-way analysis of variance (ANOVA) (age-by-sex) for unbalanced designs with 
Tukey post hoc tests was used to compare growth and metabolic parameters in YM-, YF-, OM-, 
and OF-hMPCs. The growth parameters compared include percent dead tAUC, live nuclei 
nAUC, confluency nAUC, saturation density, and population doubling time. To normally 
distribute the residuals, percent dead tAUC, live nuclei nAUC, and confluency nAUC values 
were log transformed prior to calculating the two-way ANOVA. The metabolic parameters 
include baseline OCR, stressed OCR, OCR metabolic potential, baseline ECAR, stressed ECAR, 
ECAR metabolic potential, OCR/ECAR ratio, and glucose uptake. Three-way ANOVA (age-by-
sex-by-time) was used with a Tukey post hoc test and a Bonferroni correction to compare YM-
hMPCs, YF-hMPCs, OM-hMPCs, and OF-hMPCs for percent dead, live nuclei count, and 
percent confluency over time. Three-way ANOVA (age-by-sex-by-time) was also used with a 
Bonferroni correction to compare mRNA levels of PPARGC1α, CD36, GLUT1, and GLUT4 
over time. All statistical tests for mRNA data were performed on the delta Cp values for all 
genes. Biologically meaningful comparisons (YM-hMPCs vs. YF-hMPCs, YM-hMPCs vs. OM-
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hMPCs, YF-hMPCs vs. OF-hMPCs, and OM-hMPCs vs. OF-hMPCs) are reported for all 
parameters measured. Pairwise results for two- and three-way ANOVAs are presented if the 
interaction term is significant. Statistics were completed using R. All values are reported as mean 
± s.d. Significance was determined at p < 0.05.  
 
2.4 Results 
2.4.1 Effect of age and sex on hMPC expansion capacity 
To determine whether age and sex impact expansion capacity, we compared expansion 
parameters of YM-, YF-, OM- and OF-hMPCs over 408 h, while cells were incubated in GM. To 
capture cell death throughout expansion, we determined the percentage of dead cells every 24 h 
for 408 h. For percentage of dead cells throughout expansion (Figure 1A), we observed a 
significant age-by-sex-by-time interaction (p<0.001). Post hoc analysis revealed that within 
young-hMPCs, YF-hMPCs had a greater percentage of dead cells early in proliferation (24 and 
48 h, p<0.05, Figure 1A) compared to YM-hMPCs. Within old-hMPCs, OM-hMPCs had a 
greater percentage of dead cells throughout proliferation (24, 120, 168, and 216 h; p<0.05) when 
compared to OF-hMPCs. Within male-hMPCs, OM-hMPCs had a greater percentage of dead 
cells throughout proliferation (24-120, 168, 216 h; p<0.05) compared to YM-hMPCs. Within 
female-hMPCs, OF-hMPCs had a greater percentage of dead cells at 72 and 96 h of proliferation 
(72-96 h, p<0.05) when compared to YF-hMPCs. To determine the magnitude of total cell death 
throughout expansion, we also determined the percent dead total area under the curve (tAUC) for 
each group (Figure 1B); we observed a significant age-by-sex interaction (p<0.001). Post hoc 
analysis indicated that within young-hMPCs, YF-hMPCs had significantly greater percent dead 
tAUC compared to YM-hMPCs (p<0.01). Within male-hMPCs, OM-hMPCs had significantly 
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greater percent dead tAUC compared to YM-hMPCs (p<0.001). We observed no significant 
differences in percent dead tAUC between old- or female-hMPCs.  
To fully characterize growth characteristics over time, we measured live nuclei count and 
percent confluency every 24 h for 408 h. For live nuclei count (Figure 1C), we observed a 
significant age-by-sex-by-time interaction (p<0.001). Post hoc analysis indicated that within 
young-hMPCs, YF-hMPCs had a fewer number of live cells throughout expansion (192-260, 408 
h; p<0.05). Within male-hMPCs, OM-hMPCs had fewer live nuclei throughout expansion (168-
408 h, p<0.05) compared to YM-hMPCs. We observed no significant post hoc analyses within 
old-hMPCs or within female-hMPCs. We calculated live nuclei net area under the curve (nAUC) 
as a measure of the overall magnitude of live cell count throughout expansion (Figure 1D). For 
live nuclei nAUC, we observed a significant age-by-sex interaction (p<0.01). Post hoc analysis 
revealed that within young-hMPCs, YF-hMPCs had a trending lower nAUC (p=0.06). Within 
male hMPCs, OM-hMPCs had a significantly lower live nuclei nAUC (p<0.001). We observed 
no sex-related differences in the old-hMPCs or age-related differences in female-hMPCs for live 
nuclei nAUC. For percent confluency (Figure 1E), we observed a significant age-by-sex-by-
time interaction (p<0.001). Post hoc analysis revealed that within young-hMPCs, YF-hMPCs 
had a lower percent confluency throughout proliferation (168-264 h, p<0.05) when compared to 
YM-hMPCs. Within male-hMPCs, OM-hMPCs had a lower percent confluency throughout 
proliferation (144-408 h, p<0.05) compared to YM-hMPCs. We observed no difference in 
percent confluency between female- or old-hMPCs. For percent confluency nAUC (Figure 1F), 
we observed a significant age-by-sex interaction (p<0.01). We observed no difference in percent 
confluency nAUC between YF-hMPCs and YM-hMPCs. Within male-hMPCs, OM-hMPCs had 
a significantly lower percent confluency nAUC compared to YM-hMPCs (p<0.001). We 
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observed no difference in percent confluency nAUC between old- or female-hMPCs.  
Our final measured growth parameters were population doubling time (Figure 1G) and 
saturation density (Figure 1H). For population doubling time, we observed a significant age-by-
sex interaction (p<0.001). Post hoc analysis revealed that within old-hMPCs, OM-hMPCs had 
significantly longer population doubling times compared to OF-hMPCs. Within male hMPCs, 
OM-hMPCs had a significantly longer population doubling time compared to YM-hMPCs. We 
observed no differences within young-hMPCs or within female-hMPCs. For saturation density, 
we observed a significant age-by-sex interaction (p<0.01). Post hoc analysis revealed a 
significantly lower saturation density in YF-hMPCs compared to YM-hMPCs (p<0.05) and 
significantly lower saturation density in OM-hMPCs compared to YM-hMPCs (p<0.001). We 
observed no significant differences within old-hMPCs or within female-hMPCs.  
Collectively, this evidence suggests that within young-hMPCs, YF-hMPCs have a lower 
expansion capacity than YM-hMPCs. Additionally, male-hMPCs are severely impacted with 
age; OM-hMPCs have impaired expansion capacity when compared to YM-hMPCs. To the 
contrary, female-hMPCs are largely unaffected with age; OF-hMPCs do not have significantly 
impaired expansion capacity compared to YF-hMPCs.   
 
2.4.2 Effect of age and sex on markers of cell cycle and cell apoptosis 
 To probe more deeply into alterations in pathways related to cell expansion, we leveraged 
an existing RNAseq dataset that included all YM-, YF-, OM-, and OF-hMPC samples at the 3rd 
day of rapid expansion. Based on our cell expansion data, we were particularly interested in 
identifying canonical pathways and cellular and molecular functions that were differentially 
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expressed between OM- and YM-hMPCs and between YF- and YM-hMPCs. We identified 571 
DEgenes between OM- and YM-hMPCs that had a q value (False Discovery Rate) <0.01. We 
identified 395 DEgenes between YF- and YM-hMPCs that had a q value of <0.01. Significantly 
up- and down-regulated canonical pathways are reported in Table 2 and Table 3 for the age 
comparison in males and sex comparison in young, respectively. Significantly up- and down- 
regulated molecular and cellular functions are reported in Table 4 and Table 5 for the age 
comparison in males and sex comparison in young, respectively. Briefly, the canonical pathways 
and cellular and molecular functions support decreased cell cycling and increased cell death in 
OM- compared to YM-hMPCs and in YF- compared to YM-hMPCs.  
 
2.4.3 Effect of age and sex on markers of metabolism throughout expansion 
 After determining that expansion capacity is altered with age and sex, especially in male-
hMPCs, we next asked whether hMPC metabolism is impacted by age and sex during expansion. 
We measured both oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
to capture the metabolic phenotype under baseline and stressed (stimulated to maximize energy 
production) conditions. The metabolic phenotype of each age-by-sex hMPC comparison, under 
baseline and stressed conditions, is shown in Figure 2. For baseline OCR (Figure 3A), we 
observed a significant age-by-sex interaction (p<0.01). Post hoc analysis revealed that within 
young-hMPCs, YF-hMPCs had a significantly lower baseline OCR when compared to YM-
hMPCs. Within male-hMPCs, OM-hMPCs had a trending lower baseline OCR (p=0.09). We 
observed no significant post hoc differences within female-hMPCs or old-hMPCs. We observed 
no significant main-effects or interactions for stressed OCR (Figure 3B). For OCR metabolic 
potential, we observed a significant age-by-sex interaction (p<0.05) (Figure 3C). Post hoc 
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analysis revealed that within old-hMPCs, OM-hMPCs had a significantly greater OCR metabolic 
potential when compared to OF-hMPCs. Within male-hMPCs, OM-hMPCs had a significantly 
greater OCR metabolic potential (p<0.01), suggesting OM-hMPCs used less of their OXPHOS 
capacity during expansion. There were no significant differences in OCR metabolic potential 
within young- or female-hMPCs. We observed no significant main-effects or interactions for any 
ECAR measure (Figure 3D-3F), the OCR/ECAR ratio (Figure 3G), or glucose uptake (Figure 
3H). Interestingly, the ECAR metabolic potential was significantly greater than the OCR 
metabolic potential during expansion (age-by-sex-by-measure interaction p<0.05, Figure 4), 
suggesting that cells used the majority of their OXPHOS capacity during expansion but had a 
glycolytic reserve that could be used to meet an energy demand. Post hoc analysis revealed 
significantly higher ECAR metabolic potential versus OCR metabolic potential in YM-hMPCs 
(p=0.1), YF-hMPCs (p<0.05), and OF-hMPCs (p<0.05). OCR and ECAR metabolic potential 
was not significantly different in OM-hMPCs.  
Importantly, we identified that baseline OCR was negatively correlated with percent dead 
tAUC (Figure 5). This suggests that hMPCs that had the lowest baseline OCR also had the 
greatest cell death throughout expansion and further supports the importance of OCR during 
hMPC expansion.  
 To complement the Seahorse measurements, we also quantified the expression of genes 
related to substrate uptake (CD36, GLUT1 and GLUT4) and mitochondrial biosynthesis 
(PPARGC1A). We observed significant main-effects of time (p<0.05) for both PPARGC1A 
(Figure 6A) and CD36 (Figure 6B). Expression of both genes significantly increased over time 
in all groups, indicating that hMPCs may increase OXPHOS and fatty acid uptake throughout 
proliferation. For glucose uptake genes, we observed significant age-by-sex interactions for 
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GLUT1 (p<0.0001) (Figure 6C) and GLUT4 (p<0.05) (Figure 6D). Post hoc analysis revealed 
that within old-hMPCs, OM-hMPCs had significantly greater expression of GLUT1 (p<0.001) 
and GLUT4 (p<0.001) compared to OF-hMPCs. Within male-hMPCs, OM-hMPCs had 
significantly greater expression of GLUT1 (p<0.001) and GLUT4 (p<0.001) compared to YM-
hMPCs. No significant difference in GLUT1 or GLUT4 expression was detected within young- 
and female-hMPCs. We did not observe changes in glucose uptake in accompaniment to 
observed increases in GLUT1 gene expression. However, this may be due to the sensitivity of 
our glucose uptake assay.  
 
Table 2. Differentially Expressed Canonical Pathways between OM- and YM-hMPCs 
OM- vs. YM-hMPCs   
Canonical Pathways P-value Z-score 
Mitotic Roles of Polo-Like Kinase 1.0E-07 -2.1 
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 3.8E-05 1.4 
Cyclins and Cell Cycle Regulation 2.3E-04 -2.3 
P53 Signaling 2.3E-03 1.9 
Pyrodixal 5’-phosphate Salvage Pathway 1.4E-03 -1.9 
Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I 2.6E-03 -2.0 
Salvage Pathways of Pyrimidine Ribonucleotides 3.5E-03 -2.1 
 
 
Table 3. Differentially Expressed Canonical Pathways Between YF- and YM-hMPCs 
YF- vs. YM-hMPCs   
Canonical Pathways P-value Z-score 
Mitotic Roles of Polo-Like Kinase 2.2E-08 -1.7 
Cell Cycle: G2/M DNA Damage Checkpoint Regulation  2.2E-07 1.7 
Cyclins and Cell Cycle Regulation 9.8E-05 -2.1 
Pyridoxal 5’-phosphate Salvage Pathway 1.1E-03 -2.5 
Role of BRAC1 in DNA Damage Response 9.0E-05 -1.3 
Salvage Pathways of Pyrimidine Ribonucleotides 1.8E-03 -2.6 
Cell Cycle: G1/S Checkpoint Regulation 6.9E-03 1.3 
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Table 4. Molecular and Cellular Functions of DEgenes (OM- vs. YM-hMPCs) 
Molecular and Cellular Functions P-value Z-score # Molecules 
Cell cycle progression 4.2E-29 -1.2 121 
M phase 9.7E-21 -1.7 44 
Interphase 1.2E-20 -1.6 80 
Segregation of chromosomes 4.4E-20 -2.0 32 
G1/S phase transition 9.5E-09 -1.7 26 
Senescence of cells  1.7E-08 2.4 31 
Necrosis 9.4E-30 2.3 217 
Cell death 7.6E-27 2.0 248 
Apoptosis 1.4E-26 2.0 209 
 
 
Table 5. Molecular and Cellular Functions of DEgenes (YF- vs. YM-hMPCs) 
Molecular and Cellular Functions P-value Z-score # Molecules 
Cell cycle progression 5.8E-28 -1.7 96 
Mitosis 8.9E-28 -1.2 64 
Segregation of chromosomes 9.5E-24 -2.1 31 
M phase 2.7E-21 -1.9 38 
Interphase 3.0E-13 -2.0 53 
S phase 1.8E-09 -1.7 25 
G1/S phase transition 2.0E-06 -2.6 18 
Segregation of chromosomes 9.5E-24 -2.1 31 
Repair of DNA 1.5E-09 -2.8 28 
Apoptosis 3.6E-20 2.2 148 
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Figure 1. Expansion Characteristics of Young and Old Male and Female hMPCs. A) 
percentage of dead cells every 24 h over 408 h of growth, B) percent dead total area under the 
curve (AUC), C) live nuclei count every 24 h over 408 h of growth, D) live nuclei net AUC, E) 
percent confluency every 24 h over 408 h of growth, F) confluency net AUC, G) population 
doubling time during the exponential growth phase, H) saturation density (number of live 
nuclei/cm2 at the proliferation plateau). Two-way ANOVAs were used with Tukey post-hoc tests 
to compare YM-, YF-, OM-, and OF-hMPCs for percent dead tAUC, live nuclei nAUC, 
confluency nAUC, saturation density, and population doubling time. Three-way ANOVAs were 
used with Tukey post-hoc tests and Bonferroni corrections to compare percent dead, live nuclei 
count, and percent confluency over 408 h of growth. All values are reported as mean ± s.d. # 
YM- vs. YF-hMPCs, β YF- vs. OF-hMCPs, κ YM- vs. OM-hMPCs, α OM- vs. OF-hMPCs. 
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Figure 2. Metabolic Phenotype of Young and Old Male and Female hMPCs. Baseline 
metabolic phenotype of YM-, YF-, OM-, and OF-hMPCs are designated by solid shapes (■ = 
YM-, ▲= YF-, ♦ = OM-, ● = OF-hMPCs). Stressed metabolic phenotype of YM-, YF-, OM-, 
and OF-hMPCs are designated by open shapes (□ = YM-, ∆ = YF-, ◊ = OM-, ○ = OF-hMPCs).  
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Figure 3. Metabolic Characteristics of Young and Old Male and Female hMPCs. A) 
Baseline oxygen consumption rate (OCR), B) stressed OCR, C) OCR metabolic potential 
(stressed – baseline), D) baseline extracellular acidification rate (ECAR), E) stressed ECAR, F) 
ECAR metabolic potential, G) baseline ratio of OCR/ECAR, H) glucose uptake. Two-way 
ANOVAs were used with Tukey post-hoc tests to compare YM-, YF-, OM-, and OF-hMPCs for 
all parameters. All values are reported as mean ± s.d. # YM- vs. YF-hMPCs, β YF- vs. OF-
hMCPs, κ YM- vs. OM-hMPCs, α OM- vs. OF-hMPCs. p<0.05 
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Figure 4. OCR and ECAR Metabolic Potential. Metabolic potential of OCR vs. ECAR in all 
groups. A two-way ANOVA was used with Tukey post-hoc tests to compare OCR and ECAR 
metabolic potential in all groups. All values are reported as mean ± s.d. * p<0.05 
 
 
 
 
 
 
 
Figure 5. Baseline OCR and Percent Dead Correlation. Pearson correlation of percent dead 
tAUC and baseline OCR. p<0.05 
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Figure 6. Gene Expression in Young and Old Male and Female hMPCs A) PPARGC1α, B) 
CD36, C) GLUT1 and D) GLUT4 mRNA levels at 1st and 3rd day of rapid expansion. Three-way 
ANOVAs were used with Tukey post-hoc tests and Bonferroni corrections for all mRNA targets. 
All values are reported as mean ± s.d. # YM- vs. YF-hMPCs, β YF- vs. OF-hMCPs, κ YM- vs. 
OM-hMPCs, α OM- vs. OF-hMPCs. p<0.05 
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2.5 Discussion 
 This is the first research to evaluate age- and sex-related differences in the expansion 
capacity of primary hMPCs and to identify differences in metabolism that underlie and thus 
likely impact hMPC expansion capacity. Expansion capacity is the ability of cells to undergo cell 
division but minimize cell death, senescence, or premature differentiation, thus, maximizing the 
number of cells that are able to be used for repair and regeneration of tissue. Expansion of the 
hMPC pool following injury is an essential component of the SkM regeneration process (4). It 
has been documented that aged SkM has a decreased capacity for recovery following injury (21). 
In vitro, animal MPC models have demonstrated age-related reductions in total nuclei count and 
elevation in cell death during expansion (34, 159). However, our experiments using hMPCs 
suggest that age-related differences in MPC expansion are sex-specific and not due to a main-
effect of chronological aging per se. Importantly, hMPCs largely retain the human donor, 
metabolic phenotype and have the most relevant genetic background to address age- and sex-
related differences in hMPC expansion capacity and metabolism (1). Use of isolated and cultured 
SCs do limit the ability to understand the role of the tissue niche, which has been shown to play a 
critical role in the muscle regeneration process (193). Impaired muscle regeneration with age is 
likely due to a combination of intrinsic changes within SCs and extrinsic changes within the 
tissue niche (193). 
 
2.5.1 Continual, heightened cell death impairs expansion capacity of old male hMPCs  
hMPCs from healthy older males had reduced expansion capacity compared to their 
younger counterparts, but hMPCs from healthy females were largely unaffected by age. Both 
OF- and OM-hMPCs had heightened cell death early in expansion. However, OF-hMPCs were 
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able to minimize cell death and largely maintain their expansion capacity. This contrasts with 
OM-hMPCs that had continued, heightened cell death and impaired expansion capacity as 
evidenced by lengthened population doubling times, impaired confluency, and a lowered 
saturation density. The impaired expansion phenotype of the OM-hMPCs was supported by 
differential expression of genes that are related to (i) increased DNA damage checkpoint control, 
p53 signaling, apoptosis, and senescence; and (ii) decreased cyclins and cell cycle control.  
Heightened cell death was also observed as a contributor to reduced expansion capacity 
in YF-hMPCs compared to YM-hMPCs. While YF-hMPCs (vs. YM-hMPCs) also had 
differential expression of genes involved in (i) increased DNA damage checkpoint control and 
apoptosis; and (ii) decreased cyclins and cell cycle control, the number of DEgenes related to 
these functions was lower than the aging male-hMPC comparison. Additionally, in the YF-
hMPCs vs. YM-hMPCs comparison, senescence of cells was not identified as a functional 
category for DEgenes. Intriguingly, unlike the male-hMPCs, female-hMPCs were largely 
unaffected by age. This contrasts evidence from mouse models. Mouse primary MPCs (mMPCs) 
derived from male mice at 40, 60, or 120 days of age all exhibited higher proliferation rates than 
age-matched female mMPCs, suggesting male mMPCs have greater expansion capacity, 
independent of age (108). However, sex-related differences in expansion capacity were based on 
total nuclei counts only; the number of dead cells was not quantified. As we have identified in 
this study, there are significant age- and sex- related differences in cell death that greatly impact 
total hMPC number. Thus, measuring only total nuclei as a proxy of cell expansion may 
overestimate the culture’s expansion capacity. Differences between studies may also indicate 
species-specific differences in MPC expansion. Overall, we identified heightened cell death in 
hMPCs from old males, which diminished the number of cells available for myogenesis.  
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Notably, only three old male cultures expanded well enough to be used in the 
experiments reported here. Thus, the difference between OM- and YM-, YF-, or OF-hMPCs may 
be even greater in the general population than suggested in this study. Age related changes at the 
whole tissue and cellular level in muscle have been previously dichotimized by sex (144). In 
vivo, SkM mass makes up a greater percentage of total body mass in males compared to females; 
however, males lose SkM mass at a faster rate and lose almost twice the strength that females 
lose with age (69, 80, 135, 144, 195). Additionally, females tend to preserve muscle quality 
(strength per unity of muscle) better than males with age (97). The data we present here agree 
with these previous reports; hMPCs from males have the greatest alterations in phenotype and 
expansion capacity with age. Thus, the predominant mechanisms driving muscle loss with age 
appear sex dependent. 
 
2.5.2 OXPHOS is impaired in old male hMPCs  
Results from our study also suggest that reduced expansion capacity in OM-hMPCs was 
accompanied by alterations in measurements of OXPHOS while glycolysis was maintained. The 
OM-hMPCs that remained viable had slightly reduced OXPHOS, but similar glycolytic activity 
and greater GLUT1 mRNA levels compared to YM-hMPCs. It is unclear whether the cells that 
survived in OM-hMPC cultures were protected or harmed by lower OXPHOS. Lower OXPHOS 
reduces the potential for oxidative stress and related cell damage, assuming there are no 
impairments in any of the electron transport chain complexes (3). Thus, reduced OXPHOS may 
have protected surviving OM-hMPCs. Similarly, surviving SCs, isolated from cadavers four days 
post mortem, consumed less oxygen, produced lower levels of ATP, and existed at a lower 
metabolic state compared to freshly isolated cells (92); reduced metabolic activity may promote 
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cell survival. An alternative and more likely hypothesis is that lower basal respiration indicates 
an inability to meet energy demands and/or an impairment in one or more of the electron 
transport chain complexes. Impairments in the electron transport chain can increase reactive 
oxygen species (ROS) production and decrease energy production (120). Increased ROS 
generation and/or reduced energy production may subsequently impair hMPC expansion 
capacity. Interestingly, following an OXPHOS stressor, OM-hMPCs had the equivalent oxygen 
consumption capacity as YM-hMPCs, suggesting that OM-hMPCs preferentially used glycolysis 
over OXPHOS. In support of this theory, SCs that underwent replicative aging also had 
alterations in mitochondrial OXPHOS and favored glycolysis (128). Furthermore, a metabolite 
analysis of whole SkM demonstrated lower TCA cycle intermediates and lower ATP levels in 
healthy older males compared to young males (51). Additionally, our study suggests that higher 
rates of baseline OXPHOS are correlated with a lower percent dead throughout expansion. 
Collectively, this evidence suggests that OXPHOS is necessary to meet energy demands and 
promote cell survival throughout hMPC expansion.  
Contrary to the OM-hMPCs, OF-hMPCs maintained markers of both OXPHOS and 
glycolysis at similar levels as those in YF-hMPCs, despite lower expression levels of the glucose 
transporters GLUT1 and GLUT4. Similarly, SCs isolated from a female infant and passaged until 
replicative senescence displayed increased OCR and reduced glucose flux as cells approached 
senescence (12). Overall, our results suggest that sex-specific alterations in metabolism occur 
with age and may underlie sex-specific alterations in expansion capacity.  
Supporting the importance of OXPHOS for expansion, expression of genes related to 
fatty acid uptake and OXPHOS (CD36 and PPARGC1A) increased throughout expansion in all 
age-by-sex hMPC cultures. In accordance, Ryall et al. reported an increase in mitochondrial 
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fluorescence and an enrichment of genes known to regulate the TCA cycle in primary mMPCs 
after 48 h in culture (154). Additionally, Cerletti et al. demonstrated that enhanced OXPHOS 
capacity in mMPCs achieved through caloric restriction increased proliferation and improved 
transplant efficiency (25). Thus, while studies have reported the importance of glycolysis early in 
cell proliferation (93, 154), our results as well as those of others support that increasing 
OXPHOS capacity may be important for later stages of proliferation (148, 154) and 
differentiation (93, 162). 
 
2.5.3 Heterogeneity within cell cultures 
An alternative hypothesis to the observed sex-specific, age-related differences in hMPCs 
is that there is metabolic heterogeneity in our cultures despite sorting for SC specific markers 
(191). Rossi et al. recently characterized two distinct SC populations using cells freshly isolated 
from Sprague-Dawley wild-type rats (150). The two populations, termed Low Proliferative 
Clones [(LPC) myogenic fate] and High Proliferative Clones [(HPC) spontaneously produce 
adipocytes], were separated according to their proliferative capacity and metabolic profiles 
(150). While both LPC and HPC cells were isolated using SC specific markers, only LPC cells 
expressed a marker of myogenic commitment (MyoD) after 10 days in culture and had a greater 
myogenic regeneration potential when transplanted in vivo (150). Interestingly, LPC cells had 
elevated mitochondrial ATP production and OXPHOS, while HPC cells were more likely to be 
sensitive to oxidative stress (150). Similarly, Rocheteau et al. identified two subpopulations of 
SCs in Tg:Pax7-nGFP mice in vivo and in vitro; the Pax7Hi population of SCs (vs. Pax7Lo cells) 
had greater expression of genes related to stemness and lower metabolic activity as evidenced by 
lower ATP levels (147). It is likely that similar metabolic heterogeneity exists in hMPC cultures 
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and the heterogeneity changes with age and sex of the donor. However, the presence of 
subpopulations in human cultures remains unexplored.  
 
2.6 Conclusion 
In summary, this is the first research to identify heightened cell death and altered 
metabolism as age-related intrinsic differences that contribute to altered expansion capacity of 
hMPCs. Importantly, these age-related differences in expansion and metabolism were sex-
specific. hMPCs derived from older males exhibited the greatest cell death and expansion 
impairment while hMPCs derived from older females were largely unaffected by age. Our results 
highlight the importance of quantifying both live and dead cell counts when measuring 
expansion capacity. Furthermore, OM-hMPCs exhibited alterations in markers of OXPHOS 
while OF-hMPCs maintained OXPHOS function. We conclude that the underlying contributors 
to impairments in expansion capacity that occur with age are largely sex-dependent and may be a 
function of altered metabolism.  
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3.1 Abstract 
Primary human muscle progenitor cells (hMPCs) are commonly used to understand 
skeletal muscle biology, including the regenerative process. Variability from unknown origin in 
hMPC expansion capacity occurs independent of disease, age, or sex of the donor. We sought to 
determine the transcript profile that distinguishes hMPC cultures with greater expansion capacity 
and to identify biological underpinnings of these transcriptome profile differences. Sorted 
(CD56+/CD29+) hMPC cultures were clustered using unbiased, K-means cluster analysis into 
FAST and SLOW based on growth parameters (saturation density and population doubling 
time). FAST had greater expansion capacity indicated by significantly reduced population 
doubling time (-60%) and greater saturation density (+200%), nuclei area under the curve (AUC, 
+250%), and confluency AUC (+120%). Additionally, FAST had fewer % dead cells AUC (-
44%, p<0.05). RNAseq was conducted on RNA extracted during the expansion phase. Principal 
component analysis distinguished FAST and SLOW based on the transcript profiles. There were 
2205 differentially expressed genes (DEgenes) between FAST and SLOW (q value ≤ 0.05); 362 
DEgenes met a more stringent cut-off (q value ≤ 0.001 and 2.0 fold-change). DEgene enrichment 
suggested FAST (vs. SLOW) had promotion of the cell cycle, reduced apoptosis and cellular 
senescence, and enhanced DNA replication. Novel (RABL6, IRGM1, and AREG) and known 
(FOXM1, CDKN1A, Rb) genes emerged as regulators of identified functional pathways. 
Collectively the data suggest that variation in hMPC expansion capacity occurs independent of 
age and sex and is driven, in part, by intrinsic mechanisms that support the cell cycle.    
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3.2 Introduction  
Stem cells [satellite cells (SC)] are essential for skeletal muscle repair and regeneration 
following damage. SC and a well-orchestrated program leads to muscle progenitor cells (MPCs) 
that develop into multinucleated muscle cells (myofibers) or self-renew the SC pool. In vivo, 
dysfunction and loss of SCs leads to pathological remodeling and eventually to functional 
decline of the muscle (60). To date, much research has used animal models to understand SC 
biology and skeletal muscle regeneration (34, 36, 108, 122, 147). Characterization of human 
MPC (hMPC) biology is currently limited and is necessary to understand the basic biology of 
human skeletal muscle regeneration and to develop and use hMPCs in stem cell therapies.  
Interindividual variability in skeletal muscle regeneration is becoming more appreciated 
(41, 182); however, the biological underpinnings of regenerative variability are unclear. hMPCs 
maintain properties of their in vivo state (1, 71); thus, hMPCs are advantageous for the study of 
human variability in the regenerative response. Regeneration requires the proliferation and 
expansion of MPCs to create adequate cells to fuse into mature myofibers (99, 140, 151). In 
mice, depletion of SCs by genetic modification impedes myocyte fusion and skeletal muscle 
regeneration (88). Previous reports demonstrate that age of human/mouse MPCs impacts primary 
MPC proliferation rates (15, 28, 34, 108). We and others have demonstrated, however, that not 
all old hMPCs have impaired expansion capacity and similarly, not all young hMPCs expand 
better than old hMPCs (165). This raises the question, what are the biological underpinnings of 
expansion capacity of hMPCs?  
Using unbiased statistical clustering tools, such as K-means cluster analysis, samples can 
be clustered by phenotypic similarity versus by the commonly used categorical similarity. 
Clustering by phenotypic similarity allows us to identify and understand basic biological 
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differences that underlie a phenotype (11, 169). Using tools such as principal components 
analysis (PCA), we can also unbiasedly cluster samples based on transcript profile similarity to 
determine whether the transcript profile underlies observed differences in phenotype (124, 190). 
The overarching goals of the proposed research were to determine the transcript profile(s) that 
distinguishes the expansion capacity of hMPCs independent of age and sex, and to identify 
biological underpinnings of expansion capacity. Understanding and even predicting hMPC 
expansion capacity of donor cells will further our understanding and utilization of hMPCs for 
research and therapy.   
 
3.3 Methods 
3.3.1 Ethical approval 
All studies were approved by the Cornell University, Institutional Review Board. Written 
informed consent was obtained from all participants. 
 
3.3.2 Human skeletal muscle procurement  
Young and old, males and females were recruited for participation in this study. Young 
and old participants met the screening age range cutoffs of 22-40 y and 60-85 y respectively. All 
individuals completed a comprehensive health history and physical activity questionnaire and 
were independently ambulatory and cognitively intact (as determined by the examining nurse 
practitioner). Individuals were excluded for contagious infections and any chronic, end-stage 
disease expected to limit life-expectancy to less than one year, induce anorexia, or restrict 
physical activity. Individuals with seated resting systolic blood pressure >140 mmHg or diastolic 
blood pressure >90 mmHg and individuals receiving anabolic (e.g., GH, IGF-I) therapy were 
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also excluded.  
Skeletal muscle biopsies were performed by a nurse practitioner in the Human Metabolic 
Research Unit (HMRU) at Cornell University. After an overnight fast, subjects reported to the 
HMRU, vitals were measured, and subjects rested in the supine position. A percutaneous needle 
biopsy of the vastus lateralis was taken using a 5.0 mm Bergstrom biopsy needle with suction 
under local anesthetic (1% lidocaine). Tissue was quickly blotted with sterile gauze, and visible 
adipose and connective tissues were removed. Skeletal muscle aliquots were either snap frozen 
in liquid nitrogen and stored at -80°C or were placed in Gibco® Hibernate®A (Thermo Fisher 
Scientific) and stored at 4°C.  
 
3.3.3 Purified, primary human skeletal satellite cells  
Primary human SCs were obtained from the biopsy tissue of young males (n=6, average 
age = 29 y), old males (n=3, average age = 72 y), young females (n=13, average age = 29 y), and 
old females (n=7, average age = 71 y). Approximately 75-100 mg of muscle biopsy tissue was 
stored in Gibco® Hibernate®A (Thermo Fisher Scientific) at 4°C until tissue disassociation was 
performed; dissociation occurred within 48 h of the biopsy. After mincing and washing via 
gravity with Ca-Mg free D-PBS, the tissue was disassociated in digest medium [2 mg/mL 
Collagenase D (Roche) in low-glucose DMEM]. After 30 minutes in digest medium, fresh digest 
medium and dispase were added. The disassociating pellet was titurated until a uniform slurry 
was achieved. Growth medium [(GM) Hams F12 + 20% FBS + 5ng/mL bFGF (Promega) + 1% 
Pen/Strep (Gibco)] was added to the slurry and passed through a 70 um cell strainer into a sterile 
conical tube. The cell suspension was centrifuged and the achieved pellet was resuspended in 
Recovery® freezing medium (Gibco) and cryopreserved at -80°C. Thawed cells were seeded on 
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a type-I collagen coated culture dish (initial cell confluency ~15%) (178). After 24 h, the GM 
was replaced with fresh GM and further replenished every 48 h. Once cells reached ~70% 
confluency, they were removed from the plate using 0.05% trypsin and passaged. Cells were 
expanded to passage four, then cryopreserved in 10% DMSO + GM.  
To purify the culture, approximately 1-1.5 million cells were labeled with fluorescently-
conjugated antibodies specific for myoblast cell surface antigens CD56 (NCAM; PE-Cy7-
conjugated) and CD29 (β1-integrin; AlexaFluor488-conjugated) and the viability stain 7-
Aminoactinomycin D (7AAD) (191). Individual samples yield 150,000 – 800,000 viable 
CD56+/CD29+ hMPCs per 1 million cells sorted using a BD FACS Aria™ Fusion flow 
cytometer. Sorted CD56+/CD29+ cells (>98% positive) were expanded in culture by passaging 
twice and then used in experiments; all in vitro experiments were performed using sorted cells at 
passage six. Due to high rates of cell death, only three old male cultures yielded sufficient 
hMPCs to be sorted and used in experiments.     
 
3.3.4 Expansion measurements  
Sorted hMPCs were seeded at a density of approximately 10% and proliferated in GM for 
408 h. GM was changed every 48 h. Confluency, nuclei count, and percent dead in each culture 
were measured every 24 h after seeding using the Celigo® S, Imaging Cytometer (Nexcelom 
Bioscience), a high-throughput, microplate based, brightfield and fluorescent imaging system. In 
this way, we performed repeated measures of confluence, nuclei counts, and live/dead cell 
counts. Live cells were measured every 24 h by co-staining cells with Hoescht 33342 (to identify 
nuclei) and fluorescently labeled propidium iodide (to identify dead cells). Propidium iodide 
positive cells were subtracted from Hoescht 33342 positive cells to determine the total number of 
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live cells. The number of propidium iodide positive cells were divided by the number of Hoescht 
33342 positive cells to determine the percentage of dead cells. Using percent confluency and live 
nuclei counts, we determined live nuclei net area under the curve (AUC), net confluency AUC, 
percent dead total AUC, population doubling time, and saturation density (the number of live 
nuclei at growth plateau divided by area of the well) for each culture.   
 
3.3.5 Clustering hMPC cultures via growth parameters 
K-means clustering using Euclidean distance was used to unbiasedly separate cultures 
into two clusters [fast growing cluster (FAST) and slow growing cluster (SLOW)] based on the 
growth parameters population doubling time and saturation density. The data was checked for 
outliers by identifying any samples that had a distance ≥ 2.5 standard deviations from the cluster 
mean; no outliers were identified. FAST had significantly faster population doubling times 
(Figure 1A) and greater saturation densities (Figure 1B) compared to SLOW. It is important to 
highlight that K-means clustering separated the hMPC cultures independent of age and sex of the 
donor. The number of males and females as well as the average age, weight, and BMI of the 
participants in each cluster are presented in Table 1. Although the age range was similar between 
clusters, the average age of participants in the FAST cluster was significantly younger than 
participants in the SLOW cluster.   
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Table 1. Participant Demographics 
Cluster Sex  
(M/F) 
Age 
(years)* 
Age Range 
(years) 
Weight  
(kg) 
BMI  
(kg/m2) 
FAST 6/7 31 ± 13 21-68 70.9 ± 14.6 23.7 ± 3.3 
SLOW 3/13 53 ± 22 25-80 67.0 ± 12.2 25.1 ± 5.1 
All values are Mean ± SD. 
* p<0.05 
Total n = 29 
 
3.3.6 RNA isolation and integrity  
RNA was harvested from sorted cells using TRK lysis buffer (Omega) following 
manufacturer’s instructions at the third day of rapid expansion. The first day of rapid expansion 
was defined as the first increase in percent confluency that was ≥ 5%. RNA was harvested after 
120 h of proliferation for samples that never had an increase in percent confluency ≥ 5% in a 24 
h interval. Total RNA was purified using an EZNA total RNA kit (Omega) following 
manufacturer’s instructions. Total RNA quantity was determined spectrophotometrically and an 
RNA quality number (RQN) was generated via sample quality control (QC). A subgroup of 
samples from each cluster was chosen for RNA sequencing (RNAseq). Samples were chosen 
based on RNA quality, age, and sex. To eliminate biased age and sex effects, we aimed to 
balance age and sex in each cluster. All RNA samples submitted for RNA sequencing had an 
RQN > 7. The number of males and females as well as the average age, weight, and BMI of 
participants that were sequenced in each cluster are presented in Table 2.  
 
Table 2. Participant Demographics from RNAseq Samples 
Cluster Sex  
(M/F) 
Age  
(years)* 
Age Range 
(years) 
Weight  
(kg) 
BMI 
(kg/m2) 
FAST 4/3 35 ± 17 21-68 73.8 ± 16.0 24.0 ± 3.2 
SLOW 3/5 63 ± 21 26-80 66.8 ± 13.3 25.2 ± 5.0 
All values are Mean ± SD.  
* p<0.05 
Total n = 15 
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3.3.7 RNAseq   
 
            TruSeq-barcoded RNAseq libraries were generated with the NEBNext Ultra II RNA 
Library Prep Kit (New England Biolabs). Each library was quantified with a Qubit 2.0 (dsDNA 
HS kit; Thermo Fisher) and the size distribution was determined with a Fragment Analyzer 
(Advanced Analytical) prior to pooling. Libraries were sequenced on a NextSeq500 instrument 
(Illumina). At least 20M single-end 75 bp reads were generated per library. Reads were trimmed 
for low quality and adaptor sequences with cutadapt v1.8 (parameters: parameters: -m 50 -q 20 -a 
AGATCGGAAGAGCACACGTCTGAACTCCAG --match-read-wildcards) (109). Reads were 
mapped to the reference genome/ transcriptome using tophat v2.1 (parameters: --library-type=fr-
firststrand --no-novel-juncs -G <ref_genes.gtf>) (85). Cufflinks v2.2 (cuffnorm/cuffdiff) was 
used to generate the fragments per kilobase of transcript per million mapped reads (FPKM) 
values and statistical analysis of differentially expressed genes (DEgenes) (176). DEgenes met a 
minimum q value cut-off of < 0.05.  
 
3.3.8 PCR validation  
Total RNA quantity and quality was determined spectrophotometrically, followed by 
cDNA synthesis using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). We selected and validated five DEgenes that were identified as having differential 
expression between FAST and SLOW in the RNAseq dataset. Genes chosen to validate were 
selected as follows: four genes were previously shown to be involved in myoblast proliferation 
(E2F2, HGF, PDGFRA, FOXM1), and one gene was randomly selected via a random number 
generator (EGR1). We used real-time, quantitative PCR, performed using the LightCycler 480 
system (Roche) with the TaqMan Fast Advanced Master Mix and TaqMan® Gene Expression 
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Assays (Applied Biosystems), to identify differences in gene expression of select genes. 
Primer/probes used were as follows: E2F2 (Hs00918090_m1), HGF (Hs00300159_m1), 
PDGFRA (Hs00998018_m1), EGR1 (Hs00152928_m1), and FOXM1 (Hs01073586_m1). TBP 
(Hs00427621_m1) was used as the housekeeper. 
 
3.3.9 Principal component analysis  
Principal component analysis (PCA) of the log2FPKM values was used to reduce the 
dimensionality and unbiasedly cluster the RNAseq data. Briefly, FPKM values were converted to 
log2FPKM values. The gene list was trimmed to include only genes for which at least two 
samples had FPKM ≥ 2.0 and the log2FPKM was at least a 2.0-fold change across samples. JMP 
was used to complete the PCA on the covariances of the trimmed gene list. Eigenvectors, 
eigenvalues, and principal components were determined.     
 
3.3.10 Pathway analysis 
Ingenuity Pathway Analysis (IPA) was used to identify canonical pathways, functional 
classifications, upstream regulators, and networks discovery. The software was set to analyze 
transcripts with a fold change ≥ 2.0 and FDR corrected q value ≤ 0.001.  
 
3.3.11 Statistical methods 
Statistical tests used to analyze differences in growth parameters were performed using R 
and Prism 4 (GraphPad). For comparisons between two groups, t-tests were performed in Prism 
4.0. For a comparison over time (i.e., confluency, live nuclei count, and percent dead), a two-
way ANOVA (cluster-by-time) for unbalanced designs was performed in R. When interactions 
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were significant, a pairwise comparison with Bonferonni correction was performed for each 
time-point in R. Significance was determined at p < 0.05. 
 
3.4 Results  
3.4.1 Expansion phenotype of the FAST and SLOW clusters 
After we separated hMPC cultures into FAST and SLOW clusters using K-means cluster 
analysis (based on population doubling time and saturation density), we quantified differences 
between FAST and SLOW for all expansion measurements. Compared to samples in the SLOW 
cluster, samples in the FAST cluster had more live cells at each 24 h measurement between 120-
408 h of growth (Figure 2A) and more live cells in total throughout expansion (Figure 2B). 
Similarly, samples in the FAST cluster had a greater percent confluency every 24 h from 96-408 
h of growth (Figure 2C) and a greater percent confluency in total throughout growth (Figure 
2D) compared to samples in the SLOW cluster. Samples in the FAST cluster also had a lesser 
percentage of dead cells from 24-144 h and 168-192 h of growth (Figure 2E) and a lesser 
percentage of dead cells in total throughout expansion compared to the SLOW (Figure 2F).  
 
3.4.2 RNAseq and pathway enrichment 
PCA was used to determine whether the transcript profile, determined using RNAseq, 
could unbiasedly cluster the hMPC cultures into the same growth parameter clusters (i.e. FAST 
vs. SLOW). PC1 accounted for 85% of the variability while PC2 accounted for 4% of the 
variability in the data (Figure 3). While PC1 and PC2 clustered the samples into the same FAST 
and SLOW clusters, PC2 was largely responsible for this separation. Aligning with the 
separation of cultures into FAST and SLOW, the top 30 DEgenes driving PC2 (Table 3) were 
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classified by IPA into Molecular and Cellular Functions (Table 4). PC1 accounted for the largest 
amount of variability in the data, but it did not distinguish the cultures clearly into FAST and 
SLOW, suggesting there is a large amount of variability not accounted for by growth parameters. 
Genes driving PC1 are shown in Table 5.   
 
Table 3. Top 30 Genes Driving PC2 
Gene Name PC Score  
(Absolute Value) 
Gene Name PC Score  
(Absolute Value) 
TNNT2 
TMEM8C 
SOX8 
MT3 
LCE3A 
RARRES2 
HLA-DRB1 
TGM3 
CRIP1 
UTS2R 
STMN2 
PTGDS 
LOC389033 
SFRP4 
CPXM1 
 
7.4 
7.0 
6.1 
6.0 
5.7 
5.4 
5.3 
5.3 
5.2 
5.1 
5.1 
5.0 
5.0 
4.9 
4.9 
 
FRMPD1 
COMP 
MYL4 
KPRP 
FAM101A 
PSG4 
CD24 
RTN4RL1 
SPINK13 
PENK 
LCE2A 
ATP1A2 
L1CAM 
CA2 
WBSCR27 
 
4.9 
4.8 
4.8 
4.8 
4.7 
4.7 
4.7 
4.6 
4.6 
4.6 
 
4.5 
4.5 
4.5 
4.4 
4.4 
 
 
 
Table 4. Functions of *DEgenes Driving PC2 
**Molecular and Cellular Function # DEgenes in Pathway 
Cell Death and Survival 89 
Cell Cycle 
Cellular Assembly and Organization 
37 
29 
DNA Replication, Recombination, and Repair 36 
*DEgenes, differentially expressed genes 
**Functional annotation determined using Ingenuity Pathways Analysis 
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Table 5. Top 30 Genes Driving PC1 
Gene Name PC Score 
(Absolute Value) 
Gene Name PC Score 
(Absolute Value) 
H19 
TGFBI 
FN1 
SERPINE2 
ASS1 
PLAU 
TAGLN 
TIMP1 
HMGA1 
IGFBP3 
HTRA1 
MMP2 
PLAT 
SPARC 
SERPINE1 
 
35.0 
33.3 
30.5 
30.0 
27.6 
27.3 
27.1 
27.1 
27.0 
26.4 
25.8 
25.6 
25.0 
24.2 
23.7 
  
CTSD 
VKORC1 
ANPEP 
PTX3 
PTTG1IP 
TPM1 
MT1E 
IGFBP7 
SNHG5 
LOX 
DKK1 
ALDH1A1 
IFITM3 
ITGBL1 
ERRFI1 
 
23.3 
23.3 
23.3 
22.5 
22.3 
22.3 
22.3 
22.2 
21.8 
21.5 
 
  21.4 
  21.4 
  21.3 
  21.3 
  21.2 
 
 
To determine biological underpinnings for observed differences in hMPC expansion 
capacity, DEgenes between FAST and SLOW were determined. We identified 2204 DEgenes 
with a (FDR) q value < 0.05. All DEgenes were expressed in both FAST and SLOW clusters and 
met the minimum FPKM cutoff of 2.0. To validate the RNAseq results, five genes were selected 
for RT-PCR analysis (see methods). Similar to the RNAseq data, all five genes had significantly 
greater expression in the FAST compared to the SLOW, confirming the RNAseq results (Figure 
4). 
IPA was used to identify pathway enrichment for DEgenes. Of the 2204 DEgenes, 362 
DEgenes (173 upregulated and 189 downregulated) met a cutoff of fold change ≥ 2.0 and a 
stringent FDR of q value ≤ 0.001. The top 10 up- and down-regulated genes are reported in 
Table 6. A total of 50 functional classifications were identified at the p < 0.05 level. Sub-
functions within each functional classification are associated with a z-score that indicates 
predicted activation (increased or decreased) of the sub-function based on the directional change 
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of the DEgenes. Out of the top 10 functional classifications, four were of particular interest to us 
(Cell Cycle, Cellular Assembly and Organization, DNA Replication Recombination and Repair, 
and Cell Death and Survival). The most highly activated and deactivated sub-functions within 
these functional classifications are reported in Table 7; redundant sub-functions were collapsed. 
As anticipated, FAST cultures had functions that suggest activation of Cell Cycle Progression, 
Cell Proliferation, and Cell Survival, but deactivation of Apoptosis and Senescence of Cells. In 
addition, we analyzed the top networks created by the DEgenes. The top four networks of 
DEgenes had functions related to DNA Replication, Recombination and Repair; Cellular 
Function and Maintenance; Cellular Assembly and Organization (Network 1, Score = 50, 
Figure 5), Cell Cycle, Cellular Assembly and Organization, Reproductive System Development 
and Function (Network 2, Score = 50, Figure 6), Cell Cycle; DNA Replication, Recombination, 
and Repair; and Cellular Assembly and Organization (Network 3, Score = 42, Figure 7), and 
Cell Cycle, Connective Tissue Disorders, and Developmental Disorder (Network 4, Score = 40, 
Figure 8). Of particular interest, several known and novel regulators of cell proliferation were 
nodes in the top 4 networks. These nodes include ERK1/2, E2F, FOXM1, CCNA1, and Rb.  
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Table 6. Top 10 Up- and Down-Regulated DEgenes 
DEgene Expression Log Ratio Q Value (FDR) 
Upregulated in FAST   
TRPA1 
CHI3L1 
PENK 
CA2 
CPXM1 
COLEC12 
PDGFRA 
FOXF1 
COL15A1 
CACNG7 
3.5 
3.2 
2.9 
2.8 
2.7 
2.5 
2.3 
2.3 
2.3 
2.2 
7.21E-04 
7.21E-04 
7.21E-04 
7.21E-04 
7.21E-04 
7.21E-04 
7.21E-04 
7.21E-04 
7.21E-04 
7.21E-04 
Downregulated in FAST   
COMP 
TNNT2 
SOST 
LCE3A 
PRRT4 
RARRES2 
MYOG 
TGM3 
SORCS1 
STMN2 
-3.6 
-3.6 
-3.6 
-3.6 
-3.4 
-3.3 
-3.3 
-3.2 
-2.7 
-2.7 
5.00E-05 
5.00E-05 
5.00E-05 
5.00E-05 
5.00E-05 
5.00E-05 
2.00E-04 
5.00E-05 
5.00E-05 
5.00E-05 
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Table 7. Functional Classification of DEgenes 
Functional Pathway Sub-function P value *Activation 
z score 
Cell Cycle Interphase 2.0E-10 3.8 
 Cell cycle progression 5.1E-15 2.9 
 Senescence of cells 1.2E-05 -2.2 
Cellular Development, Cellular 
Growth and Proliferation 
Cell proliferation of tumor cell 
lines 
3.3E-09 3.4 
Cell Death and Survival Cell survival 5.3E-09 3.0 
 Cell viability 1.4E-08 2.6 
 Apoptosis 2.8E-13 -2.8 
DNA Replication, 
Recombination, and Repair 
Chromosomal aberration 3.0E-08 -2.2 
 Metabolism of DNA 2.7E-09 2.5 
 DNA replication 6.6E-08 2.4 
*Positive z score, predicted activation is increased; negative z score, predicted activation is 
decreased 
 
A total of 36 canonical pathways were identified at p < 0.05. Like sub-functions, 
increased and decreased activity of canonical pathways is inferred based on the z-score. Highly 
activated canonical pathways included Mitotic Roles of Polo-like Kinase (z-score 2.3, p value 
1.09E-08), Estrogen-Mediated S-phase Entry (z-score 1.9, p value 1.66E-07), and Cyclins and 
Cell Cycle Regulation (z-score 2.6, p value 3.71E-04). Intriguingly, deactivated canonical 
pathways included checkpoint regulation of the cell cycle: CHK Proteins in Cell Cycle 
Checkpoint Control (z-score -2.2, p value 4.28E-05), Cell Cycle G2/M DNA Damage Checkpoint 
Regulation (z-score -2.2, p value 1.29E-03) and Cell Cycle G1/S Checkpoint Regulation (-1.3, p 
value 4.81E-03). 
 Identifying upstream regulators provides additional insight into the modulators 
responsible for the observed DEgenes between FAST and SLOW. We identified several 
regulators using both the Upstream Analysis and Regulator Effects tools in IPA (Table 8). 
Several of the top upstream regulators, identified based on DEgenes, are related to regulation of 
the cell cycle; regulators that promote cell cycle (e.g. E2F2) had prediction scores that suggested 
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increased activity in FAST compared to SLOW, while regulators that inhibit the cell cycle (e.g. 
CDKN1A, Rb) had prediction scores that suggested decreased activity in FAST compared to 
SLOW.  
 
Table 8. Predicted Upstream Regulators  
Gene Molecule Type *Activation Z-Score P Value 
FOXM1 Transcription Regulator 4.7 1.5E-21 
RABL6 Other 4.9 6.8E-33 
Irgm1 Other -3.3 8.7E-11 
MED1 Transcription Regulator 3.1 1.0E-05 
AREG Growth Factor 4.6 1.2E-18 
CDKN1A Kinase -3.7 1.7E-38 
Rb Group -3.2 4.1E-15 
E2F2 Transcription Regulator 2.4 1.2E-16 
*Positive z score, predicted as activated; negative z score, predicted as inhibited 
 
 
 
Figure 1. Determinants of FAST and SLOW Clusters. A) Population doubling time during 
exponential growth and B) saturation density (number of live nuclei/cm2 at the proliferation 
plateau) were used to separate FAST and SLOW clusters using K-means clustering. T-tests were 
used to compare clusters for saturation density and population doubling time. All values are 
reported as mean ± s.d. **p<0.01, ***p<0.001. Total n=29 (n=13 in FAST, n=16 in SLOW).  
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Figure 2. Growth Characteristics of FAST and SLOW Clusters. A) Live nuclei count every 
24 h over 408 h of growth, B) live nuclei net area under the curve (AUC), C) percent confluency 
every 24 h over 408 h of growth, D) confluency net AUC, E) percentage of dead cells every 24 h 
over 408 h of growth, and F) percent dead total AUC. Two-way ANOVA with Bonferroni 
correction was used to compare clusters at each time point for live nuclei count, percent 
confluency, and percentage of dead cells. T-tests were used to compare clusters for live nuclei 
net AUC, confluency net AUC, and percent dead total AUC. All values are reported as mean ± 
s.d. *p<0.05, **p<0.01, ***p<0.001. Total n=29 (n=13 in FAST, n=16 in SLOW). 
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Figure 3. Principal Components Analysis. Principal Component Analysis (PCA) show larger 
separation of samples between identified growth phenotype clusters than within identified 
growth phenotype clusters. PCA revealed that 85% of gene expression data could be explained 
by PC1. PC2 accounted for 4% of the variability in the data. Each dot represents an individual 
transcriptome from a participant. Closed square = Young Male-hMPCs, closed circle = Young 
Female-hMPCs, open square = Old Male-hMPCs, open circle = Old Female-hMPCs. Total n = 
15 (n=7 in FAST, n=8 in SLOW).  
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Figure 4. Validation of DEgenes. Plot comparing the fold-change between RT-PCR and 
RNAseq for 5 genes that were upregulated in the FAST Cluster. Total n = 15 (n=7 in FAST, n=8 
in SLOW).  
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Figure 5. Network 1. The top network of DEgenes had functions related to DNA Replication, 
Recombination and Repair; Cellular Function and Maintenance; Cellular Assembly and 
Organization. Of particular interest, ERK1/2 (a known regulator of cell proliferation) was 
identified as a primary node in this network.  
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Figure 6. Network 2. The second network of DEgenes had functions related to Cell Cycle, 
Cellular Assembly and Organization, Reproductive System Development and Function. Of 
particular interest, FOXM1 (a novel regulator of MPC proliferation) was identified as a primary 
node in this network.  
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Figure 7. Network 3. The third network of DEgenes had functions related to Cell Cycle; DNA 
Replication, Recombination, and Repair; and Cellular Assembly and Organization. 
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Figure 8. Network 4. The forth network of DEgenes had functions related to Cell Cycle, 
Connective Tissue Disorders, and Developmental Disorder. Of particular interest, CCNA1, Rb, 
and E2F were identified as primary nodes in this network.  
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3.5 Discussion 
Primary hMPCs are an important research model used to understand skeletal muscle 
biology and the regenerative process. Additionally, hMPCs have the potential to be used for 
therapy. However, there are recognized challenges in using primary hMPCs for both research 
and therapy, including the limited understanding of human cells (14). There is also a large degree 
of variation in the expansion capacity among donor cultures, which limits the potential for use of 
hMPCs. Using K-means cluster analysis and measurements of culture population doubling time 
and saturation density, we are the first to unbiasedly cluster cultures with similar growth 
parameters, which allowed us to identify drivers of expansion capacity that weren’t related to 
categorical age or sex. It is important to note that the participants whose cultures clustered into 
the FAST cluster were significantly younger on average than participants whose cultures 
clustered into the SLOW cluster. However, the age range for both clusters included both young 
and old participants. Additionally, a greater percentage of females clustered into the SLOW 
cluster compared to the FAST cluster. These observations agree with previous research which 
suggests reduced myoblast proliferation with advancing age (113, 159) and in female (vs male) 
cultures (108). While sex differences in proliferation may be attributable to differences in sex 
hormones, increasing evidence suggests these differences may be innate (7, 41). Furthermore, 
using this methodology, we determined that the transcript profile can distinguish donor cultures 
based on their expansion capacity (FAST and SLOW). Our primary findings demonstrate that 
cultures with enhanced expansion capacity have DEgenes enriched in functional classifications, 
pathways and networks that suggest promotion of the cell cycle, reduced apoptosis and cellular 
senescence, and enhanced DNA replication. Novel and known regulators of the cell cycle 
emerged as having important roles in these functional pathways. 
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3.5.1 Promotion of the cell cycle  
As expected, when DEgenes were analyzed for functional classifications, pathways, and 
networks, we identified that FAST had an enrichment of DEgenes that suggested 
activation/promotion of the cell cycle and proliferation. In total, 82.0% of genes related to Cell 
Cycle Control of Chromosomal Replication (the top canonical pathway) and 66.7% of genes 
related to Mitotic Roles of Polo-Like Kinase (the second canonical pathway) were upregulated in 
the FAST cluster. TRPA1 and CHI3L1 were two of the most highly upregulated genes in FAST 
cells. While the specific function of TRPA1 has not yet been determined, recent evidence 
suggests it promotes myoblast migration and plays a functional role in skeletal muscle repair 
(126). Similarly, CHI3L1 has been shown to activate myoblast proliferation (70). The prediction 
score of upstream regulators further supports promotion of the cell cycle in FAST and inhibition 
of the cell cycle in SLOW. We identified several novel upstream regulators, including RABL6, 
IRGM1, and AREG, which have been shown to promote cell proliferation in cancer models, but 
have not been associated with functional roles in hMPCs (47, 67, 158, 168). Intriguingly, 
FOXM1, another predicted upstream regulator, was recently shown to be essential for the 
proliferation and survival of satellite cells (30). These upstream regulators likely interact to 
enhance hMPC proliferation in the FAST cluster.  
In agreement with previous literature, we also identified several known regulators of 
hMPC proliferation in our analysis. The fourth network identified by IPA had nodes related to 
two of the top upstream regulators, CDKN1A (p21) and Rb. CDKN1A induces cell cycle arrest 
by inhibiting cyclin dependent kinase activity, a key regulator of cell cycle initiation and 
progression (119). Machida and Booth demonstrated that SCs from aged animals, which have 
reduced proliferation, have increased nuclear p21WAF1/CIP1 and p27Kip1 (105). Rb also induces cell 
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cycle arrest by inhibiting transcription factors of the E2F family; E2F transcription factors push 
cells into S phase and promote progression through the cell cycle (119). E2F was predicted to be 
an “active” upstream regulator in the FAST and CDKN1A and Rb were predicted to be 
“inhibited”. Thus, cells in the FAST cluster have predicted activation of cell cycle activators and 
predicted inhibition of cell cycle inhibitors.  
An alternative hypothesis to reduced cell proliferation in SLOW (vs. FAST) is that 
SLOW cultures prematurely differentiate, despite the presence of growth factors in the growth 
medium. In support of this hypothesis, our data demonstrate that MYOG, a marker of muscle 
differentiation, is upregulated 9.8 fold in the SLOW hMPCs compared to FAST. Collectively our 
data suggest that reduced expansion capacity in SLOW cultures may be due to a combination of 
processes including reduced cell cycle progression, increased cellular apoptosis, increased 
cellular senescence, and perhaps premature differentiation.  
 
3.5.2 Reduced apoptosis and cellular senescence  
DEgenes were enriched in apoptosis, cellular senescence, and cell survival functional 
classifications; differences in gene expression support promotion of apoptosis and cellular 
senescence and suppression of cell survival in cultures with reduced expansion capacity (i.e. in 
the SLOW cultures). There are several possible reasons for increased cellular senescence or cell 
death in SLOW cells. As alluded to below, SLOW cells may have ineffective DNA repair 
mechanisms, leading to increased cellular apoptosis (149). Alternatively, SLOW cells may 
experience SC exhaustion, a feature that occurs when cells senesce and are no longer able to 
divide (111). SC exhaustion has been reported to occur secondary to aging (111). However, we 
demonstrate here that SC exhaustion may be a feature of not only older cells, but young cells as 
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well. Again, FOXM1 and AREG were identified as key upstream regulators for cell survival, 
reinforcing the importance of these regulators in hMPC expansion.  
 
3.5.3 Enhanced DNA replication 
One of the top functional classifications, based on network analysis of DEgenes, was 
DNA replication, recombination, and repair. The DEgenes suggest upregulation of checkpoint 
control, alignment of chromosomes, DNA replication, DNA synthesis, and DNA repair in FAST 
cells. These results further support that FAST cells are better able to enter into S phase and 
promote progression of the cell cycle. Additionally, 91.2% of genes associated with the role of 
BRCA1 in the DNA damage response were upregulated in the FAST cluster. BRCA1 is a well 
characterized tumor suppressor gene that functions in DNA damage repair, genomic stability, 
and apoptosis (189). Furthermore, a key central hub to the top network was ERK1/2. ERK1/2 has 
been shown to play critical roles in promoting cell proliferation, partly through promotion of the 
DNA damage response (184). Activation of the BRCA1 and ERK1/2 pathways in FAST cells 
may promote DNA repair and prevent apoptosis, thus enhancing hMPC expansion capacity.  
 
3.5.4 DEgenes that are not specific to the expansion of hMPCs 
PC1, which accounted for 85% of variability in the gene expression data, did not 
distinguish the growth parameter clusters. Intriguingly, PC1 did not distinguish cultures by age 
or sex either. The top genes of PC1 were related to signaling pathways that have been previously 
identified as important for SC expansion including TGF and Wnt signaling (2, 27). Thus, 
although PC1 identified several previously known regulators of SC expansion, the underlying 
cause of these differences in gene expression between samples remains unknown. 
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3.5.5 Clinical implications 
 In humans, the degree of skeletal muscle hypertrophy has been associated with SC 
expansion and incorporation of SCs, as new nuclei, into myofibers (myonuclear addition) (134). 
Adults who had an extreme response to resistance exercise training (RT) achieved significantly 
greater myofiber hypertrophy compared to individuals with modest or no/minimal (non) 
response. These extreme responders had a significantly greater number of SCs at baseline, a 
significant increase in the number of SCs following RT, and the greatest myonuclear addition 
compared to other responder groups. Intriguingly, the whole tissue SkM transcript profile that 
distinguished the extreme and non-responders prior to RT contained several of the same 
DEgenes that we identified in FAST during expansion (169). Because not all of the DEgenes 
between the two studies were regulated in the same direction, future studies are needed to 
understand the relationship between expansion capacity of the SC and the hypertrophic and 
myonuclear addition capacity.  
 
3.5.6 Limitations 
A potential limitation of our research is use of passage six hMPCs. It is recognized that 
proliferative capacity declines with passaging (106). However, it is intriguing that some hMPCs 
maintain their expansion capacity. We have tracked the hMPCs from passage 2 to passage 7; we 
observed no difference in expansion parameters between passage 2 and passage 7 (data not 
shown). We have not tracked expansion parameters beyond passage 7. We and others (66) have 
demonstrated that FACS conducted on tissue digest provides only 10-15 satellite cells per 
milligram of skeletal muscle tissue. Thus, distinguishing populations of hMPCs that maintain 
expansion capacity is necessary for addressing scientific inquiries and utilization in therapies. 
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3.7 Conclusion  
The regenerative capacity of hMPCs differs by many conditions including chronological 
age (38, 64) and perhaps the sex (165) of the donor. However, there is a large degree of 
variability in expansion capacity that comes from an unknown origin. Using a novel model of 
hMPC expansion and unsupervised approaches, we identified that a transcript profile underlies 
the culture to culture variability in hMPC expansion. We identified functional pathways and key 
regulators that distinguish cultures with greater expansion capacity. The transcript profile 
suggests maintenance of the cell cycle in FAST but an induction of cell cycle inhibitors in 
SLOW cultures. 
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4.1 Abstract 
 
 Acute inflammation following muscle injury is an integral component of the regenerative 
response. However, chronic muscle inflammation impairs the regenerative capacity of skeletal 
muscle (SkM). Previous research has identified muscle inflammatory susceptibility (MuIS), or 
the ability to manage and respond to inflammation, as a predictor of failed muscle regeneration 
and regrowth following surgery. We sought to determine the transcript profile that distinguishes 
human muscle progenitor cell (hMPC) cultures with high and low inflammatory susceptibility 
(MuIS+ and MuIS-, respectively). Sorted (CD56+/ CD29+) hMPC cultures from young adults 
were clustered using unbiased K-means and hierarchical clustering into MuIS+ and MuIS- 
clusters independent of sex. MuIS+ had greater expression of the inflammatory cytokines TNFα, 
IL1β, and IL6 in the absence and presence of exogenous TNFα. RNAseq was conducted on RNA 
extracted after five days in differentiation media. Principal component analysis distinguished 
MuIS+ and MuIS- based on the transcript profile. There were 2269 DEgenes between MuIS+ 
and MuIS-, with fold change ≥ 2.0 and a q value (corrected for multiple hypothesis testing) ≤ 
0.05, and 573 DEgenes that met a more stringent cutoff of q ≤ 0.001 and FC ≥ 2.0. DEgene 
enrichment suggested that MuIS+ cells had promotion of inflammatory pathways and inhibition 
of muscle differentiation pathways. MuIS+ cells also had significantly reduced expression of 
genes involved in the calcium signaling canonical pathway. Novel (KISS1) and known 
(SMARCA4, MYOD1, IL1β) genes emerged as regulators for identified functional pathways. 
Collectively the data suggest that hMPC inflammatory susceptibility is an intrinsic cell 
characteristic and occurs independent of the age or sex of the donor.  
 
 
 
 
 81 
4.2 Introduction  
 
Skeletal muscle (SkM) regeneration following muscle damage is imperative to maintain 
SkM structure and function throughout the lifespan (173). Regeneration requires a complex 
series of events involving acute inflammation, activation of SkM specific stem cells [satellite 
cells (SCs)], followed by proliferation and differentiation of committed myoblasts [muscle 
progenitor cells (MPCs)], and formation/repair of functional multinucleated muscle cells (29). 
Acute inflammation is essential for the regenerative response (192). Upon injury, macrophages 
secrete pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα) and 
interleukin 1β (IL1β) (32). SkM cells can also synthesize TNFα, and TNFα acts in an 
autocrine/paracrine manner (96).   
 TNFα has positive effects on the early stages of myogenesis, promoting the proliferation 
and aggregation of myoblasts (166). To the contrary, chronic inflammation is associated with 
pathological remodeling of the SkM and muscle atrophy (37, 83). TNFα destabilizes MyoD 
protein, inhibiting differentiation, in an NFκB dependent manner (90). In animals, intraperitoneal 
exposure to TNFα (101) and local infusion of interleukin-6 (IL-6) (75) increase protein 
catabolism and decrease SkM mass; chronic TNFα exposure via intraperitoneal injections 
depletes body proteins in rats compared to pair fed control animals (55). Merritt et al. recently 
identified a state of heightened muscle inflammatory susceptibility (MuIS+) in older adults that 
was characterized by hyperactivity of TNFα, TWEAK, and/or IL-6 signaling in the SkM and in 
isolated SCs (112). In a follow-up study, Bamman et al. dichotomized patients into MuIS+ and 
MuIS- groups based on TWEAK-R mRNA levels and demonstrated that inflammation 
susceptibility discriminates muscle anabolic potential following surgery and may predict long-
term muscle regrowth potential (10).   
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Although MuIS is an identified phenotype, the molecular mechanisms driving heightened 
MuIS remain unknown. Thus, the purpose of this study was to (i) determine the transcript profile 
that differentiates high inflammation susceptibility (MuIS+) from low inflammation 
susceptibility (MuIS-) in hMPCs and (ii) identify biological underpinnings of heightened muscle 
inflammatory susceptibility.  
 
 
4.3 Methods 
 
4.3.1 Ethical approval 
All studies were approved by the Cornell University, Institutional Review Board. Written 
informed consent was obtained from all participants. 
 
4.3.2 Human skeletal muscle procurement 
hMPCs from healthy, ambulant young males (n=6) and females (n=5) were used to 
address the objectives of this research. All individuals completed a comprehensive health history 
and physical activity questionnaire and were independently ambulatory and cognitively intact (as 
determined by the examining nurse practitioner). Individuals were excluded for contagious 
infections and any chronic end-stage disease expected to limit life-expectancy to less than one 
year, induce anorexia, or restrict physical activity. Individuals with seated resting systolic blood 
pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg and individuals receiving anabolic 
(e.g., GH, IGF-I) therapy were also excluded.  
 
4.3.3 Purified, primary human muscle progenitor cells 
Primary human SCs were obtained from the vastus lateralis muscle using the 
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percutaneous biopsy technique. The biopsy tissue was cleaned of any extraneous fascia and 
adipose tissues. Approximately 75-100 mg of the total muscle biopsy was stored in Gibco® 
Hibernate®A (Thermo Fisher Scientific) at 4°C until tissue disassociation was performed. After 
mincing and washing via gravity with Ca-Mg free D-PBS, the tissue was disassociated in digest 
medium [2mg/mL Collagenase D (Roche) in low-glucose DMEM]. After 30 minutes in digest 
medium, fresh digest medium and Dispase (Sigma) were added. The disassociating pellet was 
titurated until a uniform slurry was achieved. Growth medium [(GM) Hams F12 + 20% FBS + 
5ng/mL bFGF (Promega) + 1% Pen/Strep (Gibco)] was added to the slurry and passed through a 
70 μm cell strainer into a sterile tube. The cell suspension was centrifuged. The pellet was 
resuspended in Recovery® freezing medium (Gibco) and cryopreserved at -80°C. Thawed cells 
were seeded on a type-I collagen coated culture dish (initial cell confluency ~15%). After 24 h, 
the GM was replaced with fresh GM and further replenished every 48 h. Once cells reached 
~70% confluency, they were removed from the plate using 0.05% trypsin and passaged. Cells 
were expanded to passage four, then cryopreserved in 10% DMSO + GM.  
 
4.3.4 Fluorescence activated cell sorting 
Approximately 1-1.5 million cells were labeled with fluorescently-conjugated antibodies 
specific for myoblast cell surface antigens CD56 (NCAM; PE-Cy7-conjugated) and CD29 (β1-
integrin; AlexaFluor488-conjugated) and the viability stain 7-Aminoactinomycin D (7AAD) 
(191). Individual samples yield 150,000 – 800,000 viable CD56+/CD29+ hMPCs per 1 million 
cells sorted using a BD FACS Aria™ Fusion flow cytometer. Sorted CD56+/CD29+ cells (>98% 
positive) were expanded in culture by passaging twice and then used in experiments; all in vitro 
experiments were performed using sorted cells at passage six.  
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4.3.5 Cell culture treatments  
Sorted hMPCs were seeded at a density of approximately 10%. Throughout proliferation, 
GM was changed every 48 h. After 168 h of proliferation, hMPCs were switched to 
differentiation media [(DM) Ham’s F12 (Gibco) supplemented with 2% heat inactivated equine 
serum]. After 72 h of differentiation, cells were treated for an additional 48 h with DM alone or 
DM + 10 ng/mL TNFα (recombinant human TNFα, Millipore). DM (+/- TNFα) was changed 
every 24 h. All cells were harvested after 120 h of differentiation.  
 
4.3.6 RNA harvest and RT-PCR in differentiating cells 
RNA was harvested from sorted cells using TRK lysis buffer (Omega) following 
manufacturer’s instructions after 120 h of differentiation. Total RNA was purified using an 
EZNA total RNA kit (Omega) following manufacturer’s instructions. Total RNA quantity and 
quality were determined spectrophotometrically, and an RNA quality number (RQN) was 
generated via sample quality control (QC). cDNA was synthesized using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). We used real-time, quantitative PCR 
(RT-PCR) performed using the LightCycler 480 system (Roche) with the TaqMan Fast 
Advanced Master Mix and TaqMan® Gene Expression Assays (Applied Biosystems) to identify 
differences in gene expression of key targets related to inflammation (IL6, IL1β, TNFα), 
myogenesis (MYOG), and protein catabolism (FBX032/Atrogin-1, TRIM63/MURF1). 
Additionally, genes related to myogenesis and protein catabolism were selected for RNAseq 
validation. Primer/probes used were as follows: IL6 (Hs00985639_m1), TNFα 
(Hs01113624_g1), IL1β (HS01555410_m1), MYOG (Hs01072232_m1), FBX032 
(Hs01041408_m1), and TRIM63 (Hs00822387_m1). 18S (Hs99999901_s1) was used as the 
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housekeeper. 
 
4.3.7 Clustering via inflammatory profile 
 To determine the molecular signature differentiating MuIS+ from MuIS- cells, we 
evaluated the expression of inflammatory genes in differentiating hMPCs in the presence and 
absence of exogenous TNFα. It has previously been shown that SkM tissue that is MuIS+ has 
greater inflammation both at baseline and in response to injury, compared to MuIS- (10). Thus, 
we used K-means clustering with Euclidean distance to separate our samples, independent of age 
and sex into two clusters based on the gene expression of the inflammatory cytokines IL6, IL1β, 
and TNFα at baseline and post-TNFα treatment. We confirmed the results obtained with K-
means cluster analysis with hierarchical clustering using Euclidean distance (Figure 1). Four 
samples clustered as MuIS+, and seven samples clustered as MuIS-. IL6, IL1β, and TNFα mRNA 
levels in both clusters are shown in Figure 2A-C. Average weight, BMI, and age of participants 
in each group are presented in Table 1. There were no significant differences in age, weight, or 
BMI between the clusters. A subgroup of samples from each cluster was selected for RNA 
sequencing (RNAseq). The number of males and females as well as the average age, weight, and 
BMI of participants that were sequenced from each cluster are presented in Table 2. 
 
Table 1. Participant Characteristics  
Cluster M/F Age  
(y) 
Weight  
(kg) 
BMI 
(kg/m2) 
MuIS+ 1/3 29 ± 7.3 62.6 ± 7.2 21.6 ± 1.2 
MuIS- 5/2 28.1 ± 6.2 75.2 ± 18.7 24.5 ± 4.3 
MuIS+ = muscle inflammatory susceptibility positive  
MuIS- = muscle inflammatory susceptibility negative  
BMI = body mass index 
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Table 2. Participant Characteristics of Samples Used for RNASeq 
Cluster  M/F Age  
(y) 
Weight  
(kg) 
BMI 
(kg/m2) 
MuIS+ 1/3 29.0 ± 7.3 62.6 ± 7.2 21.6 ± 1.2 
MuIS- 4/0 24.5 ± 3.5 80.4  ± 20.2 24.6  ± 4.3 
MuIS+ = muscle inflammatory susceptibility positive  
MuIS- = muscle inflammatory susceptibility negative  
BMI = body mass index 
 
 
4.3.8 Illumina library preparation and sequencing  
To gain insight into the molecular pathways that may underlie hMPC inflammatory 
susceptibility, we performed RNAseq on a subset of samples from each group (MuIS+ n=4, 
MuIS- n=4). Total RNA quantity was determined spectrophotometrically, and an RQN number 
was generated via sample QC. All RNA samples used for RNAseq had an RQN >7. TruSeq-
barcoded RNAseq libraries were generated with the NEBNext Ultra II RNA Library Prep Kit 
(New England Biolabs). Each library was quantified with a Qubit 2.0 (dsDNA HS kit; Thermo 
Fisher) and the size distribution was determined with a Fragment Analyzer (Advanced 
Analytical) prior to pooling. Libraries were sequenced on a NextSeq500 instrument (Illumina). 
At least 20M single-end 75bp reads were generated per library. Reads were trimmed for low 
quality and adaptor sequences with cutadapt v1.8 (parameters: parameters: -m 50 -q 20 -a 
AGATCGGAAGAGCACACGTCTGAACTCCAG --match-read-wildcards) (109). Reads were 
mapped to the reference genome/ transcriptome using tophat v2.1 (parameters: --library-type=fr-
firststrand --no-novel-juncs -G <ref_genes.gtf>) (85). Cufflinks v2.2 (cuffnorm/cuffdiff) was 
used to generate Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values 
and statistical analysis to determine differentially expressed gene (DEgenes) (176).  
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4.3.9 Principal Component Analysis 
Principal component analysis (PCA) of the log2FPKM values was used to reduce the 
dimensionality and unbiasedly cluster the RNAseq data. Briefly, FPKM values were converted to 
log2FPKM values. The gene list was trimmed to include only genes for which at least two 
samples had FPKM ≥ 2 and the log2FPKM was at least a 2-fold absolute change across samples. 
JMP was used to complete the PCA on the covariances of the gene list. Eigenvectors, 
eigenvalues, and principal components were determined.  
 
4.3.10 Pathway analysis  
 
Ingenuity Pathway Analysis (IPA) was used to identify canonical pathways, functional 
classifications, upstream regulators, and networks discovery. The software was set to analyze 
transcripts with a fold change ≥ 2 and FDR corrected q value ≤ 0.001.  
 
4.3.11 Puromycin 
 
 To measure protein synthesis, puromycin incorporation into newly synthesized proteins 
was quantified using the in-cell western technique (77). Briefly, after 120 h of differentiation 
with or without TNFα treatment during the last 48 h, puromycin was spiked to achieve a 
concentration of 0.5 ng/mL. After 30 min, culture media was aspirated, and cells were fixed with 
4% paraformaldehyde and stored in sodium azide. Fixed cells were stained for puromycin using 
the following primary and secondary antibodies [Anti-Puromycin (MABE343, Millipore), 
Alexa-Fluor 488 goat anti-mouse IgG (A11029, Life Technologies)]. Images were quantified on 
the Li-Cor Odyssey® Imaging System. Puromycin was normalized to cell number in each well 
as determined by cell tag (926-41090, Licor 700 Stain).   
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4.3.12 RNAseq comparisons 
 Our RNAseq database was compared to two publically available databases downloaded 
from Gene Expression Omnibus (110, 169). Publically available RNAseq data was analyzed with 
GEO2R and uploaded into IPA. These data were then compared to our RNAseq database using 
the comparative analysis feature of IPA. 
 
4.3.13 Statistical Methods 
 
 Statistical tests used to analyze differences in mRNA and puromycin were performed 
using R. For comparisons between groups, a two-way ANOVA (cluster-by-treatment) for 
unbalanced designs was performed. Main-effects of cluster or treatment are reported if 
significance was p<0.05. We did not observe any significant interactions. 
 
4.4 Results  
4.4.1 Identification of differentially expressed genes 
 PCA was used to determine whether the transcript profile, determined using RNAseq, 
could unbiasedly cluster the hMPC cultures into the same clusters as the inflammatory cytokine 
gene expression (MuIS+ and MuIS-). PC1 accounted for 80% of the variability while PC2 
accounted for 13% of the variability in the transcript data (Figure 3). PC2 separated the clusters 
into MuIS+ and MuIS-. The inflammatory genes and inflammation related predicted upstream 
regulators driving PC2 are presented in Table 3 and Table 4 respectively. These results confirm 
the MuIS+ and MuIS- clusters and suggest that PC2 separates the inflammatory groups. 
Interestingly, the transcript profiles also largely clustered by sex, with all 3 females clustering 
into the MuIS+ group.  
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Table 3. Inflammatory Genes Driving PC2 
Target Log Ratio 
IL33 3.9 
CXCL3 3.1 
CXCL8 2.9 
CXCL6 2.3 
IL6 2.0 
CXCL1 2.0 
CXCL12 1.6 
TNFRSF14 1.2 
 
 
Table 4. Predicted Upstream Regulators of Genes Driving PC2 
Upstream 
Regulator 
Predicted Activation 
Score 
LPS 5.8 
TNF 5.0 
IL1B 4.3 
NF-kB Complex 4.0 
IKBKB 4.0 
IL1A 3.8 
TGFB1 1.6 
 
4.4.2 Validation of representative differentially expressed genes 
To determine biological underpinnings for observed differences in MuIS, we determined 
DEgenes between MuIS+ and MuIS- clusters. Using RNAseq, we identified a total of 2269 
DEgenes with fold change ≥ 2.0 and a q value (corrected for multiple hypothesis testing) ≤ 0.05. 
To validate our RNAseq results, we completed RT-PCR on five genes identified as differentially 
expressed via RNAseq. The original quantification of IL6 and IL1β confirmed the RNAseq 
results. To further validate the RNAseq results, we measured mRNA levels for MYOG, FBX032, 
and TRIM63 and compared fold change values between RT-PCR and RNAseq (Figure 4).  
 
4.4.3 RNAseq and pathway enrichment 
IPA was used for pathway enrichment of DEgenes. Of the 2269 DEgenes, IPA identified 
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573 DEgenes (178 down-regulated and 395 up-regulated in MuIS+/MuIS-) that met the cutoff of 
q ≤ 0.001 and fold change ≥ 2.0. The most highly up- and down-regulated DEgenes are 
presented in Table 5.  
 
Table 5. Up- and Down-Regulated DEgenes 
Symbol Expression Log Ratio Q Value (FDR) 
Downregulated in MuIS+ 
KISS1 -4.4 8.01E-04 
TSPAN7 -4.4 8.01E-04 
MYH7 -4.3 8.01E-04 
EEF1A2 -3.9 8.01E-04 
MYH2 -3.9 8.01E-04 
MYH1 -3.8 8.01E-04 
FOLR1 -3.8 8.01E-04 
MYH3 -3.7 8.01E-04 
TSPAN33 -3.7 8.01E-04 
ACTG2 -3.6 8.01E-04 
Upregulated in MuIS+ 
CXCL5 5.9 8.01E-04 
EPB41L3 5.2 8.01E-04 
MMP1 4.2 8.01E-04 
PCOLCE2 4.2 8.01E-04 
PENK 4.0 8.01E-04 
IFI27 3.9 8.01E-04 
GAP43 3.5 8.01E-04 
IL13RA2 3.3 8.01E-04 
ADAM33 3.3 8.01E-04 
MALAT1 3.2 8.01E-04 
 
A total of 54 functional classifications were identified at the p<0.05 level. Sub-functions 
within each functional classification are associated with a z-score that indicates predicted 
activation (increased or decreased) of the sub-function based on the directional change of the 
DEgenes. Of the top 10 functional classifications, four were of particular interest to us (Organ 
Development, Organismal Development, Skeletal and Muscular System Development and 
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Formation, and Skeletal and Muscular Disorders). The most highly activated and deactivated 
sub-functions within these functional classifications are reported in Table 6.  
 
Table 6. Functional Classifications of DEgenes 
Functional Pathway Sub-function P value Activation 
z score 
Number of 
molecules 
Organ Development Formation of Muscle 4.7E-35 -1.3 77 
Skeletal and Muscular 
System Development 
and Function 
Function of Muscle 
Contractility of muscle 
Differentiation of myoblasts 
1.1E-17 
2.4E-17 
7.4E-08 
-2.2 
-3.0 
-1.7 
48 
35 
18 
Skeletal and Muscular 
Disorders 
Inflammation 
Damage of muscle 
2.6E-08 
1.3E-07 
1.0 
2.0 
75 
14 
  
A total of 80 canonical pathways were identified at p < 0.05. Increased and decreased 
activity of canonical pathways is inferred based on the z-score. Inhibited canonical pathways 
included Calcium Signaling (z-score -3.1, p-value 7.7E-20), ILK signaling (z-score -3.0, p-value 
9.0E-09), Agrin Interactions at Neuromuscular Junction (z score -2.8, p-value 1.4E-06), Actin 
Cytoskeleton Signaling (z-score -3.8, p-value 7.4E-06), and PAK signaling (z-score -2.7, p-value 
1.1E-05). RhoGD1 signaling was the only canonical pathway significantly activated (z-score 3.1, 
p-value 7.1E-04).  
Upstream regulators are predicted to control differentially expressed downstream 
effectors. We identified several upstream regulators using the Upstream Analysis tool in IPA 
(Table 7). Regulators that promote inflammation are upregulated in MuIS+ cells, and regulators 
that promote muscle cell differentiation are downregulated in MuIS+ cells. Several of these 
upstream regulators have been shown to induce inflammation (TNF, LPS, TNFSF12, IKBKB, 
IL1B) and muscle differentiation (MYOD1, TGFB1, MEF2C, MYOCD, MYOG, NOTCH1, 
SMARCA4) previously. We have also identified additional novel regulators, including 
DNMT3B, whose role in hMPCs has not yet been shown.   
 92 
Table 7. Upstream Regulators Driving DEgenes  
Upstream Regulator Activation Z Score P value 
MYOD1 -5.0 4.9E-38 
MEF2C -3.8 6.1E-20 
MYOCD -3.6 5.7E-15 
SMARCA4 -3.1 1.7E-09 
MYOG -2.9 1.2E-14 
NOTCH1 -2.5 1.6E-10 
TGFB1 -2.1 2.4E-21 
Beta-estradiol -1.3 6.1E-27 
CHUK 1.5 2.1E-07 
IL1B 2.9 5.5E-08 
IKBKB 3.2 8.8E-09 
DNMT3B 3.3 1.3E-14 
TNFSF12 3.4 1.6E-08 
TNF 3.5 3.7E-26 
LPS 3.8 1.2E-11 
 
 
 
4.4.4 Muscle regeneration markers  
 
 Successful muscle regeneration requires acute inflammation, proteolysis, protein 
synthesis, and myoblast differentiation. Knowing that MuIS+ cells have an elevated 
inflammatory response to proinflammatory cytokines, we also investigated the effect of MuIS 
with or without cytokine exposure on markers of proteolysis, differentiation, and protein 
synthesis in MuIS+ and MuIS- cells. We observed a main-effect of MuIS cluster for FBX032 and 
TRIM63; MuIS+ cells had lower FBX032 and TRIM63 compared to MuIS- cells (Figure 8A,B). 
We observed no significant effect of MuIS on MYOG mRNA or puromycin (marker of protein 
synthesis) (Figure 8C, D).  
 
4.4.5 Clinical relevance 
 To further explore the clinical relevance of the MuIS+ phenotype, we compared our 
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transcriptomics dataset with two others previously reported in the literature (110, 169). Previous 
work had identified a transcript profile in whole muscle that distinguished extreme responders 
from non-responders in response to progressive resistance exercise training (169). Importantly, 
all transcriptomics were completed on baseline samples, prior to the start of the resistance 
training. When compared to our dataset, non-responders and MuIS+ samples had significant 
overlap in transcript profiles. A list of canonical pathways up- and down-regulated in both 
datasets is presented in Table 8.  
 
Table 8. Canonical Pathways Shared with Hypertrophic Responders to Resistance Exercise 
Canonical Pathway Non-Responders vs. 
Extreme Responders 
MuIS+ 
vs. MuIS- 
 z-score p-value z-score p-value 
Actin Cytoskeleton Signaling -3.2 1.5E-03 -3.8 7.4E-06 
Regulation of Actin-based Motility by Rho -1.5 3.0E-02 -3.3 5.2E-04 
Calcium Signaling -1.9 6.6E-04 -3.2 7.7E-20 
RhoA Signaling -1.5 3.3E-02 -3.2 3.7E-04 
Signaling by Rho Family GTPases -2.1 5.5E-02 -3.1 6.1E-03 
ILK Signaling -2.6 8.6E-02 -3.0 9.0E-09 
GNRH Signaling -2.0 9.9E-02 -1.6 2.8E-02 
Opioid Signaling Pathway -2.1 9.7E-02 -1.6 2.4E-02 
RhoGDI Signaling 2.6 2.0E-02 3.1 7.1E-04 
 
Previous work had also identified a transcript profile that distinguished young and old 
adult muscle (110). Melov et al. measured peak muscle strength and reported that older adults 
were 59% weaker than young adults. In a comparative analysis in IPA, genes differentially 
expressed in MuIS+ vs. MuIS- cultures from our dataset had significant overlap to genes 
differentially expressed in old vs. young adults, reported by Melov et al. Upstream regulators 
that are predicted to control the DEgene expression in both datasets are presented in Table 9.   
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Table 9. Upstream Regulators Shared with Older Adults  
Upstream 
Regulator 
Old Adults vs. Young Adults MuIS+ vs. MuIS- 
 z-score p-value z-score p-value 
NR4A3 -1.9 4.2E-05 -3.7 2.2E-04 
RB1 -7.6 2.5E-08 -3.3 1.6E-06 
ESRRA -2.8 5.6E-07 -3.0 1.8E-02 
KMT2D -2.4 3.3E-01 -2.8 2.3E-03 
CD3 -2.6 4.3E-02 -1.7 3.3E-02 
IGF1R -1.6 3.1E-07 -1.5 2.8E-04 
PDGF 2.9 1.5E-03 1.4 4.7E-03 
CHUK 2.2 1.3E-02 1.5 2.1E-07 
IL6 2.0 4.2E-02 1.5 2.6E-05 
ESR2 2.0 1.3E-04 1.5 7.2E-16 
IL17A 2.8 2.6E-02 1.6 6.4E-08 
MGEA5 1.2 1.9E-07 2.2 3.0E-02 
IL1 2.4 2.2E-01 2.5 4.2E-05 
IKBKG 2.2 3.1E-02 2.8 2.8E-09 
IL1B 1.2 1.0E-02 2.9 5.5E-08 
TNFSF12 1.8 6.6E-02 3.4 1.6E-08 
TNF 1.3 2.1E-05 3.5 3.7E-26 
Lipopolysaccharide 1.4 1.0E-02 3.8 1.2E-11 
KDM5A 4.0 3.4E-10 4.2 9.6E-09 
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Figure 1. Inflammatory Susceptibility Clustering. K-means and hierarchical clustering on 
inflammatory cytokine mRNA levels from control and TNFα treated cells.   
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Figure 2. Inflammatory Cytokine mRNA Levels in MuIS+ and MuIS- hMPCs. A) IL1β 
mRNA, B) IL6 mRNA, C) TNFα mRNA. For each transcript, the effect of 48 h of 10 ng/uL 
TNFα treatment on MuIS cluster was determined using a two-way ANOVA (cluster-by-
treatment) for unbalanced designs. Main-effects are reported if significance p<0.05. # = main-
effect of cluster (MuIS+ vs. MuIS-), † = main-effect of treatment (Control vs. TNFα treated).  
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Figure 3. Principal Component Analysis of RNAseq Genes. Principle Component Analysis 
(PCA) revealed that 80% of the gene expression data could be explained by PC1. PC2 explained 
13% of the variability. PCA on the RNAseq results separated the samples into the same clusters 
as the K-means and hierarchical clustering of cytokine expression data. ■ = Male-hMPCs, ▲= 
Female=hMPCs 
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Figure 4. Validation of DEgenes. Plot comparing the fold-change between RT-PCR and 
RNAseq for five genes that were differentially expressed between MuIS+ and MuIS- clusters, at 
five days of differentiation under basal conditions.  
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Figure 5. Markers of Muscle Regeneration. A) FBX032 mRNA levels, B) TRIM63 mRNA 
levels, C) MYOG mRNA levels, D) puromycin incorporation into newly synthesized proteins. 
For each marker, the effect of 48 h of 10 ng/uL TNFα treatment on MuIS cluster was determined 
using Two-way ANOVA (cluster-by-treatment) for unbalanced designs. Main-effects are 
reported if significance p<0.05. # = main-effect of cluster (MuIS+ vs. MuIS-).   
 
 
 
4.5 Discussion 
 
Using RNAseq, we are the first to identify a transcript profile that distinguishes hMPC 
cultures into MuIS clusters. Although inflammation following muscle damage is an integral part 
of the regenerative process, the ability of SkM to manage or respond to inflammation is 
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recognized as a major cause of impaired regeneration (10, 37, 112). Our primary findings 
demonstrate that MuIS+ cultures have DEgenes enriched in functional classifications, pathways 
and networks that suggest promotion of inflammatory signaling and inhibition of myoblast 
differentiation. In our analyses, novel and known regulators of inflammation and muscle cell 
differentiation have emerged as having important roles in inflammatory signaling and 
differentiation.  
  
4.5.1 Inflammatory cytokines and muscle regulatory factors 
 As expected, when DEgenes were analyzed for functional classifications and pathways, 
we identified that MuIS+ cultures had an enrichment of DEgenes related to inflammation and 
muscle damage. These RNAseq results confirm our K-means clustering. It is important to 
highlight that RNAseq was performed on cells in the absence of an exogenous inflammatory 
exposure. Our results suggest that the inflammatory status of hMPCs is a characteristic intrinsic 
to the cells, which is in agreement with the results of others (10, 112).  
  MuIS+ cultures also had a downregulation of genes related to myoblast differentiation, 
formation of muscle, and function of muscle. In hMPCs, treatment with the inflammatory 
cytokine TNFα, promotes hMPC proliferation and inhibits hMPC differentiation and fusion 
(115). TNFα is known to downregulate the transcription of the pro-myogenic transcription factor 
MYOD through NF-κB (8). Similarly, our RNAseq results suggest greater proinflammatory 
signaling and reduced myotube formation in MuIS+ cells. Additionally, TNFα has also shown to 
induce apoptosis in C2C12 myotubes (175). However, despite the increased proinflammatory 
signaling in MuIS+ cultures, our RNAseq results suggest little change in apoptosis or necrosis 
pathways.  
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4.5.2 Hormones 
  
 Unexpectedly, kisspeptin-1 (KISS1) was the most highly DEgene between MuIS+ and 
MuIS- cells; KISS1 was downregulated 21.4 fold in the MuIS+ compared to the MuIS- cultures. 
KISS1 is best known for its role in gonadotropic secretion and puberty (163). KISS1 is also 
known as a tumor metastasis suppressor in breast cancer cells; KISS1 inhibits TNFα mediated 
activation of NF-κB, which inhibits the TNFα enriched tumor microenvironment (31). While 
KISS1 has previously been reported in myocardium tissue (196), to our knowledge, we are the 
first to report the presence of KISS1 in human SkM cells. Our data suggest that KISS1 may play 
a novel and important role in the management of and response to inflammation during 
regeneration.  
 Estrogen has also been associated with a suppressed inflammatory response in SkM in 
response to injury. In our dataset, beta-estradiol signaling was predicted to be inhibited as an 
upstream regulator in the MuIS+ cluster. These results agree with previous literature; the 
protective effects of estrogen signaling have been shown in vivo. Estrogen reduced the 
inflammatory response after burn injury in human females (72) and reduced the inflammatory 
response to endotoxin exposure in post-menopausal women (136). However, despite the 
evidence for estrogen in suppressing the immune and inflammatory responses among females, 
our clusters did not depend on sex. In fact, 75% of the cultures that clustered into the MuIS+ 
group were female. Thus, in the absence of varying levels of exogenous estrogen, intrinsic 
differences in estrogen signaling, independent of sex, may play an important role in 
inflammation modulation.  
 
4.5.3 Calcium signaling 
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Calcium signaling is the most significant and highly deactivated canonical pathway in 
MuIS+ cultures when compared to MuIS- cultures. Several components of the pathway, 
including the ryanodine receptor, calmodulin, calsequestrin, and the mitochondrial calcium 
uniporter, were downregulated in MuIS+ cells. Calcium acts as a second messenger and is 
required for the regulation of many cellular processes including gene transcription, proliferation, 
and immune responses (33). Ryanodine receptor mediated calcium dynamics are required for 
skeletal myogenesis (52, 53, 198), and perturbing calcium release from internal stores impairs 
regeneration and inhibits the activation and proliferation of SCs (177). Myoblast differentiation 
is also regulated by increases in intracellular calcium (86, 87, 100); calcium-calmodulin-
dependent protein kinases (CaMK) and the calcium-calmodulin-dependent phosphatase, 
calcineurin, play significant roles in muscle cell differentiation by regulating the gene expression 
of MEF2, MYOD, and MYOG (57, 58, 103, 117). Aside from calcium’s role in muscle 
differentiation, calcium has also been implicated in the pathogenesis of immune disorders, such 
as rheumatoid arthritis (78). Celastrol, a Chinese medicinal plant, has traditionally been used to 
treat autoimmune disease and chronic inflammation (23, 179); celastrol has recently been shown 
to increase intracellular and mitochondrial calcium mobilization (194) and to decrease the 
expression of genes associated with immunity/ inflammation (40). Thus, elevated calcium 
mobilization in MuIS- cultures may play important roles in modulating both myoblast 
differentiation and inflammation.  
 
4.5.4 Epigenetics 
One of the top predicted upstream regulators controlling DEgene expression is 
SMARCA4, a member of the SWI/SNF family of proteins that are thought to regulate the 
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transcription of certain genes by altering chromatin structure (188). In primary myoblasts, 
SMARCA4 is a positive regulator of cell proliferation and survival (129) and is required for 
activation of genes in myoblast differentiation (121). SMARCA4 remodels chromatin in a 
calcium dependent manner; inhibiting calcineurin blocks chromatin remodeling, myogenic gene 
expression, and muscle cell differentiation (121). SMARCA4 also modulates the immune 
response in a variety of tissues. SMARCA4 chromatin remodeling plays an integral role in 
regulating T cell suppression of inflammation (26). To the contrary, SMARCA4 promotes the 
expression of proinflammatory genes in nonalcoholic steatohepatitis (171). In endothelial cells, 
SMARCA4 is recruited to cell adhesion molecules (glycoproteins expressed on the cell surface 
that play important roles in inflammation) via NF-κB/p65, and β-estradiol antagonizes the 
activity of SMARCA4 (49). Although the role of SMARCA4 in inflammation in other cell types 
and in myoblast differentiation have been explored, the role of SMARCA4 in modulating 
inflammation in hMPCs remains unexplored.  
 
 
4.5.5 Muscle remodeling 
 TNFα is known to promote the mRNA levels of FBX032 and TRIM63 and lead to the 
catabolism of muscle proteins (22, 84). Thus, we expected FBX032 (Atrogin-1) and TRIM 63 
(MuRF) to be elevated in MuIS+ cells. To the contrary, we observed downregulated expression 
of both FBX032 and TRIM63 in MuIS+ cultures in both the RNAseq and PCR data. Aside from 
the role of FBX032 in muscle protein catabolism, FBX032 also plays a positive role in myoblast 
differentiation through inhibiting myocardin (82). Myocardin is a transcriptional coactivator 
transiently expressed in SkM progenitor cells with inhibitory effects on the expression of MYOG 
(82). Thus, elevated FBX032 and TRIM63 expression in MuIS+ cultures may reflect increased 
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protein remodeling and enhanced myoblast differentiation.  
 In vivo, muscle remodeling occurs secondary to exercise training (48). Inflammation 
appears to be closely tied to training outcomes; older adults who gain the most strength also have 
the largest decrease in IL1β following exercise (45). The inflammatory response to exercise has 
been shown to increase, decrease, or not change depending on specific haplotype patterns. The 
exercise-induced inflammatory response is also influenced by individual SNPs (44). Thus, 
although our data suggest that a transcript profile can distinguish those with high and low muscle 
inflammatory susceptibility, differences in genotype may also play a role in distinguishing the 
groups.  
 
4.5.6 Clinical relevance 
 To further explore similarities of the MuIS+ phenotype with previously characterized 
phenotypes or disease states, we compared our transcriptomics dataset with two that have been 
published previously (110, 169). MuIS+ cultures share overlap in the gene expression profile to 
both individuals who do not respond to a progressive resistance exercise training and to older 
adults with diminished muscle strength. Importantly, all of our samples were from healthy young 
adults. This creates the question, “does the MuIS+ phenotype underlie impairment in muscle 
hypertrophy and predispose individuals to muscle loss even in the absence of old age?” 
Interestingly, when MuIS+ cultures were compared to whole tissue biopsies from those who do 
not respond to resistance training, both GnRH and calcium signaling came out as shared 
important canonical pathways. KISS-1 is known to activate GnRH signaling in other cell types, 
and KISS-1 alters the cytoskeleton in HEK293 cells (133). However, the role of KISS-1 or 
GnRH signaling in SkM has not been explored.   
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4.6 Conclusion 
Acute muscle inflammation is an integral component of SC activation and muscle 
regeneration. However, there is a large degree of variability in the ability of MPCs to manage 
and respond to inflammatory cues. Using unsupervised approaches, we identified a transcript 
profile that underlies the culture-to-culture variability in MuIS. We identified key DEgenes, 
canonical pathways, and upstream regulators that distinguish cultures based on inflammatory 
susceptibility. Uncovering the molecular determinants of muscle inflammatory susceptibility and 
SkM regeneration is important to improving clinical outcomes following muscle injury.  
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
5.1. Summary and future research for the heterogeneity in expansion capacity 
 The research presented in this dissertation indicates that expansion capacity of human 
MPCs (hMPCs) is affected by age and sex of the cell donor. Although previous research has 
investigated the impact of age and sex on expansion capacity in animal models (108, 113, 159), 
relatively little research has focused on the impact of age (6, 128) and no previous research has 
focused on the impact of sex of MPCs obtained from human SkM. We hypothesized and 
confirmed that hMPCs from older donors have a reduced expansion capacity compared to 
hMPCs from younger donors (Chapter 2). hMPCs from young female donors also have a 
reduced expansion capacity compared to hMPCs from young male donors; however, this 
comparison was not maintained with age. Old male (OM)-hMPCs had the greatest impairment in 
expansion capacity with age while hMPCs from females were largely unaffected with age. 
hMPCs from old male donors also had the greatest percentage of cell death early in expansion. 
This is the first research to identify heightened cell death as the primary contributor to altered 
expansion capacity in hMPCs.     
Catabolism of macronutrients provides the substrates and energy needed to support the 
generation of new cells and cellular structures (153). Thus, an impairment in the catabolism of 
macronutrients may negatively impact the expansion capacity of cells. To date, only one study 
has investigated the impact of chronological age (128) and no previous research has investigated 
the impact of sex on hMPC metabolic fuel preference throughout expansion. Our results suggest 
that oxidative phosphorylation (OXPHOS) is the predominant metabolic pathway used by 
healthy hMPCs during the expansion process (Chapter 2). Intriguingly, cultures from old male 
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donors had a significant disruption of OXPHOS during expansion and OM-hMPCs had the 
greatest impairment in expansion. Thus, we hypothesize that the elevated cell death and 
disruption in OXPHOS in hMPCs from old male donors contributed to the observed impaired 
expansion capacity. However, due to our experimental design, we can only state that altered 
OXPHOS is associated with impaired expansion capacity. To confirm that disruption in 
OXPHOS impairs expansion capacity, future research should inhibit OXPHOS through the use 
of small molecules (e.g. rotenone or antimycin A) and quantify changes in expansion capacity 
over time. If OXPHOS is the predominant energy source, we hypothesize that expansion 
capacity will be impaired over time.  
Despite reporting main effects of age and sex on expansion capacity, our results indicate 
that not all old hMPCs have impaired expansion capacity and similarly, not all young hMPCs 
expand better than old hMPCs (Chapter 3). The research presented in this dissertation is the first 
to use both phenotype characteristics and transcriptomics to cluster hMPC cultures into FAST 
and SLOW expanders. Using K-means clustering, an unbiased statistical clustering tool, we were 
the first to cluster samples using phenotypic similarity (FAST versus SLOW expanders) instead 
of categorical similarity (age or sex) to investigate the biological underpinnings of expansion 
capacity. In agreement with our initial work (refer to Chapter 2), the average age of participants 
who clustered into the SLOW cluster were significantly older than the average age of 
participants who clustered into the FAST cluster. Additionally, a greater percentage of females 
clustered into the SLOW cluster compared to the FAST cluster. However, both FAST and 
SLOW clusters included young and old, male and female participants. Cultures with enhanced 
expansion capacity (i.e. FAST cluster) had DEgenes enriched in functional classifications, 
pathways, and networks that suggest enhanced cell cycle, reduced apoptosis and cellular 
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senescence, and enhanced DNA replication. We identified several novel upstream regulators, 
including RABL6, IRGM1, and AREG that have been shown to promote cell proliferation in 
other cell lines (47, 158, 168); however, these regulators have not been previously identified as 
playing a role in MPC expansion let alone in MPCs from human donors. Our dataset also 
identified FOXM1 as an important upstream regulator driving the DEgenes in our FAST and 
SLOW clusters. Very recently, FOXM1 was shown to directly regulate the long noncoding 
RNAs, Snhg8 and Gm26917, that significantly regulate the proliferation and apoptosis of SCs 
(30). In the same paper, Chen et al. demonstrated that Foxm1 knockout mice and Foxm1-
knockdown C2C12 cells have decreased proliferation and increased apoptosis of SCs (30). Thus, 
one originally novel upstream regulator in our dataset has been confirmed as having an important 
functional role in SC proliferation. Future work should investigate the roles of the other novel 
upstream regulators identified in our dataset in hMPCs. Additionally, further exploration 
regarding the regulation of FOXM1 in SCs is warranted. 
Although this dissertation reports on heterogeneity between cultures, the heterogeneity 
within cultures remains unknown. Do FAST cultures expand rapidly because all cells rapidly 
divide or is the effect driven by a subset of cells? If the effect is driven by a subset of cells, do 
these cells rely on OXPHOS or glycolysis more or less than cells that divide at a slower rate? 
These questions can be probed using single cell RNAseq, where the transcriptome from each cell 
is independently sequenced. The expression levels of biologically meaningful genes, such as cell 
cycle indicators or metabolic genes can be compared using this methodology. These questions 
can also be further explored using single cell clonal expansion. Using this technique, cells are 
sorted and one cell is placed into each well of a culture plate. The rate of expansion/colonization 
of each culture derived from a single cell could be compared. Further measures of metabolism, 
 109 
gene expression, and protein expression/ activity from each clonal culture could also be 
compared. In this way, heterogeneity within FAST and SLOW cultures could be further 
evaluated.  
 
5.2 Summary and future research for the heterogeneity in inflammatory susceptibility 
 Acute inflammation is an essential component of the muscle regenerative response (192). 
However, chronic inflammation is associated with pathological remodeling of the SkM, 
including muscle loss (37, 83). Muscle inflammatory susceptibility has been reported to vary 
between individuals and to discriminate muscle anabolic potential following surgery (10). We 
are the first to explore the molecular mechanisms driving heightened muscle inflammatory 
susceptibility. Heightened muscle inflammatory susceptibility (MuIS+) clusters have elevated 
levels of pro-inflammatory cytokines at baseline and in response to exogenous cytokine exposure 
(112). MuIS+ was initially identified by Merritt et al. in tissue and hMPCs from old adults 
compared to young adults. Unlike work done by Merritt et al., we report widespread 
inflammatory variability in hMPCs from young adults. Additionally, using RNAseq, we 
identified novel and known genes that are differentially expressed between MuIS+ and MuIS- 
clusters as well as novel and known upstream regulators of inflammation and differentiation.  
 Two interesting and novel results of this study were that in MuIS+ vs MuIS- cultures 1) 
KISS-1 was the most highly differentially expressed and inhibited gene and 2) calcium signaling 
was the most significant and highly inhibited canonical pathway. When we compared our 
transcriptomics dataset to a dataset that differentiated extreme responders and non-responders to 
progressive resistance exercise training, GnRH signaling and calcium signaling were highlighted 
as important shared canonical pathways. Neither KISS-1 nor GnRH signaling have ever been 
 110 
reported as present or functional in skeletal muscle. KISS-1 inhibits TNFα mediated activation of 
NF-κB in breast cancer cells (31) and thus may play an important role in mitigating 
inflammation in MuIS- cultures. Future research should investigate the role of KISS-1 and 
GnRH signaling as well as the regulation of KISS-1 expression at the SkM cell and tissue levels. 
Additionally, calcium signaling has known roles in myoblast differentiation (86) and 
inflammation in other tissues (78). Recent research suggests that calcium mobilization may 
improve chronic inflammation and be a viable therapy for autoimmune disease (78). However, 
the role of calcium signaling in muscle inflammation remains unknown. Future research should 
investigate the role of perturbed calcium signaling on muscle inflammation and subsequent 
effects on SkM regeneration.    
 As noted above, all samples used in this dissertation were from healthy individuals. 
Interestingly, despite being free of chronic disease, muscle inflammatory susceptibility varied 
widely, even in young adults. Exploring the molecular underpinnings of muscle inflammatory 
susceptibility will provide important insight into improving therapeutic outcomes following 
injury, even in young adults. Interestingly, the transcript profiles of MuIS+ cultures also had 
remarkable overlap with older adults with diminished muscle strength. This creates the question, 
“are those with MuIS+ predisposed to muscle loss, even in the absence of chronological old 
age?” Additionally, are those with MuIS+ at higher risk for the development of sarcopenia than 
those with MuIS-? 
 
5.3 Additional uses of our model  
For all experiments presented in this dissertation, we exclusively used MPCs from 
healthy human donors. Chronic diseases including diabetes are known to impact muscle health 
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(61). Diabetes impairs energy metabolism and induces SkM atrophy and muscle weakness (61). 
Ob/ob and db/db mice have impaired myoblast proliferation and delayed muscle regeneration 
(125). Although the effects of obesity and diabetes are well characterized in animal models, little 
work has been conducted in hMPCs. The experimental techniques used in this dissertation could 
similarly be applied to investigate the molecular underpinnings of impaired hMPC expansion and 
differentiation in various disease states. 
 
5.4 Global summary 
 This dissertation highlights the heterogeneity that exists among hMPC cultures 
throughout the muscle regenerative process. Uncovering the molecular underpinnings of this 
heterogeneity is essential as the field of medicine moves towards precision therapies to improve 
human health. This dissertation utilizes –omics and unbiased clustering tools to cluster samples 
into phenotype categories aside from commonly used categorical bins, such as age and sex.  
Importantly, this dissertation highlights biologically meaningful data that would be lost if 
samples were binned using traditional techniques. Clustering samples unbiased based on 
phenotype provides insight into the pathways and regulators driving the phenotype. Although the 
phenotypes observed in hMPC cultures can also be reflected in vivo, this dissertation investigates 
intrinsic differences in hMPCs that remain outside of the tissue niche. Future research should 
follow up on the hypotheses generated in this dissertation and directly test the impact of altering 
key differentially DEgenes, upstream regulators, and canonical pathways on myoblast expansion 
and differentiation.  
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APPENDIX 
 
Satellite Cell Isolation 
 
Biopsy processing 
1. Prepare digest medium. Warm PBS and DMEM in 37°C water bath. 
2. Remove the 60-100 mg of fresh tissue stored for 24-48h in Hibernate A (Gibco) from the 
4°C refrigerator.  
3. Transfer tissue from Hibernate A to sterile petri dish in biological safety cabinet. 
4. Mince into approximately 1mm3 pieces using sterile scalpel blades. 
5. Transfer minced tissue to 15mL falcon® tube containing 10mL calcium-magnesium free 
Dulbecco’s PBS (CMF-DPBS) and allow to settle via gravity. 
6. Aspirate the supernatant, being careful not to touch the pellet. 
7. Resuspend the pellet in 10mL CMF-DPBS; Repeat steps 4-5. 
8. Resuspend the pellet in 10mL Low Glucose DMEM (Gibco); Repeat steps 4-5. 
9. Resuspend pellet in 3mL digest medium. 
10. Place suspension in water bath at 37°C for 30 min, resuspending pellet every 10-15 min. 
11. Add 83μL fresh digest medium and 24μL Dispase stock to the suspension. Return to the 
water bath. 
12. Triturate every 5-10 min using a wide bore pipet tip until a uniform slurry is achieved.  
Note: do not incubate suspension longer than 1.5 h. The majority of the tissue should be 
digested within an hour.  If not, check the age and concentration of the collagenase and 
dispase stocks. 
13. Add 6mL Growth medium to the slurry and pass through a filter by pipetting the suspension 
through 70μm cell strainer (BD falcon 352350) into a sterile 50mL conical tube. Rinse the 
strainer with an additional 4mL growth medium. 
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14. Centrifuge 300rcf for 5 minutes at room temperature (RT). 
15. Aspirate supernatant, being careful not to disturb pellet. 
Note: To prevent clumping, “flick” the pellet in minimal media, using the surface tension 
at the meniscus to disrupt the pellet prior to resuspending in liquid.  
16. Resuspend the pellet gently in 1.5mL Recovery® freezing medium (Gibco) and place in a 
controlled rate chiller (1°C/min) for a minimum of 2 hours at -80C before transferring to 
storage box (-80C) or liquid nitrogen. 
 
 
 
 
 
 
 
 
 
 
Scheme to produce high yields of low passage number cultures enriched for MPCs using the 
Celigo S Imaging Cytometer 
The total surface area of a 24 well plate and a 10 cm plate are the same.  The reason for using the 
24 well plate is to continue rapidly scanning wells daily to confirm confluence (24 well plates 
scan much more rapidly than the 10 cm plates on the Celigo). Also the time of the scan can be 
shortened by only scanning a fraction of the wells, making each confluence scan last between 3-5 
minutes before the plate is returned to the incubator.  The 10cm plates are not scanned daily, but 
their total cell counts are compared to the total cell counts of the 24 well plate and have shown not 
to differ significantly.  This shows that the rate of proliferation of the cells does not vary with the 
size (or edge effect) of the vessels.  Due to the highly motile nature of the cells, yielding variable 
coverage of the well, much more precise measurements of cell confluence are obtained with the 
Celigo as the entire wells are scanned, instead of portions of wells.  To save cells, we only 
measure confluence so the cells are not sacrificed. However, total nuclei counts could also be 
performed on single wells, thus sacrificing a very small percentage of cells per passage if using 
the 24 well plates. 
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Collagen Coating 
Collagen solution  
Prepare at time of use. Keep on ice. Do not store. 
1. Make 20mM Acetic Acid (add glacial acetic acid to 10mOhm water in fume hood). 
Water    HoAc    Collagen 
200 ml 230μL 2.8mL 
300 345 4.2 
50 57.5 0.700 
 
2. Add Type 1 Rat Tail Collagen (Corning) to a final concentration of 50μg/mL. 
3. Filter through a 0.22μm filter. 
Note: Collagen solution comes at varying concentration. Be sure to dilute appropriately.  
Note: Make only the amount of collagen solution necessary to coat the desired number of 
plates.  Keep solution on ice prior to plating. 
 
Collagen coating culture vessels 
1. Apply 5μg/cm2 freshly prepared collagen solution to vessels. 
 50μL to  each well of 96 well plate 
 250μL each well of to 24 well plate 
 2mL to each well of 6 well plate 
 8mL to 10cm plate 
2. Cover plates and leave in BSC for 12 hours (overnight). 
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3. Aspirate collagen solution and set plates on their lids, leaving them open in the BSC until 
completely dry. 
4. Store at 4°C in a sealed bag or container to maintain sterility for up to one month. 
Note: many protocols say to rinse the collagen coated wells with PBS before drying, but 
we have found that this can disrupt the collagen gel and leave a precipitate of salts on the 
surface. The purpose of rinsing is to remove any acid from the wells during the coating 
process. This is taken care of by the pre-equilibration step prior to culture. 
 
Passaging Cells 
Passage 0:  Using the processed biopsy slurry (“Participant” stored in Recovery® at -80°C 
after biopsy processing) 
1. For each biopsy slurry, add 250μL freshly prepared GM to each of 4 wells of a collagen 
coated 24-well plate. Pre-equilibrate for 1-2h at 37°C/5%CO2/Air.  To prevent 
evaporation, fill unused wells with 500μL F12 or PBS. At the same time, place freshly  
prepared GM in glass in the incubator. Leave bottle cap loose as with autoclaving to 
allow gas to reach the media. 
2. Rapidly thaw vial of P0 slurry in 37°C water bath until only very small ice crystals 
remain. 
Note: Thaw less than 5 minutes. Make sure water is NOT above 40°C.  Never trust the 
thermostat. Use a thermometer. 
3. Transfer contents of tube to a 15mL falcon tube containing 10mL Ham’s F12 + 20% FBS 
and gently but rapidly mix by inversion. 
4. Centrifuge at 300rcf for 5 min at RT in swinging bucket rotor. 
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5. Aspirate supernatant, being careful not to disturb the pellet. 
Note: Dislodge/loosen the pellet by gently “flicking” the tube, using the surface tension 
of the small amount of media remaining to help dislodge the pellet. This will help prevent 
clumping and cell death due to shear forces.  
Note: Keep cell suspensions on ice when not working with them to prevent clumping and 
adhesion to the centrifuge tube. Tubes of cells can be handled and centrifuged at RT. 
6. Gently resuspend pellet in 1mL GM.  
7. Seed P0 culture by pipetting 250μL cell suspension into each of 4 wells containing pre-
equilibrated GM in a 24 well plate. 
8. Incubate 37C/5%CO2/Air for 24 hours. 
9. Aspirate media containing debris and dead cells; replace with 500μL fresh GM. 
10. Perform baseline confluence scan using Celigo® S imaging cytometer; return to 
incubator. 
11. Replace GM containing fresh bFGF every 2 days. 
12. Perform confluence scan daily until confluence reaches 70-75%. 
Note: Passage 0 cells will often show a 2-3 day lag phase. 
 
Passage 1:  Trypsinization and splitting of passage 0 cultures (24 well plates) 
1. When confluence scan shows cells to be 75-80% confluent in all four wells of the 
passage 0 culture, pre-equilibrate one entire collagen coated 24 well plate for a minimum 
of two hours, using 250μL GM per well (total 6mL GM). 
2. Aspirate media from the 4 passage 0 wells 
3. Add 250μL 0.25% Trypsin-EDTA to each of 4 wells.  
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4. Return to incubator for 3-5 minutes, checking periodically for the state of detachment 
using a phase contrast microscope (EVOS). 
5. As soon as cells have rounded up and detached from the plate surface, pool the contents 
of the wells and transfer the resulting 1mL of cells suspended in 0.25% Trypsin-EDTA to 
5mL fresh GM in a 15mL Falcon tube to inactivate trypsin. 
6. Rinse all wells with fresh GM and pool with cell suspension in Falcon tube. 
7. Place on ice until centrifugation if processing more than one participant culture. This will 
prevent cell clumping. 
8. Centrifuge at 300 rcf for 5 min at RT. 
9. Aspirate supernatant, loosen pellet, gently resuspend with 6 mL GM. 
10. Seed each well of a 24 well plate with 250 μL suspended cells (this is a 1:6 split). 
11. Incubate 37°C/5%CO2/Air for 24 hours. 
12. Perform passage 1 baseline confluence scan using Celigo® S imaging cytometer; return 
to incubator. 
13. Aspirate media, replace with 500mL GM containing fresh bFGF every 2 days. 
14. Perform confluence scan daily until confluence reaches 70-75%. 
Note: Passage 1 cultures often do not have a lag phase. 
 
Passage 2: Trypsinization and splitting of passage 1 cultures 
1. When confluence scan shows cells to be 75-80% confluent in all 24 wells of the passage 
1 culture, pre-equilibrate passage 2 vessels: one entire collagen coated 24 well plate with 
250μL GM per well and five (5) collagen coated 10cm plates with 8mL GM per plate per 
participant culture for a minimum of two hours. 
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2. Add 250μL 0.25% Trypsin-EDTA to each of the 24 wells of the passage 1 plate. 
3. Return to incubator for 3-5 minutes, checking periodically for the state of detachment 
using a phase contrast microscope (EVOS). 
4. As soon as cells have rounded up and detached from the plate surface, pool the contents 
of the wells and transfer the resulting 6mL of cells suspended in 0.25% Trypsin-EDTA to 
a 15mL Falcon.  
5. Rinse all wells with an additional 6mL (250μL per well) fresh GM and add to falcon 
tube. 
6. Place on ice until centrifugation if processing more than one participant culture. This will 
prevent cell clumping. 
7. Centrifuge at 300rcf for 5min at RT. 
8. Aspirate supernatant, loosen pellet, gently resuspend with 6 mL GM. Place on ice until 
seeding. 
9. To each of the five 10 cm plates containing 8mL pre-equilibrated GM, add 1 mL cell 
suspension. Be sure to gently mix the suspension before pipetting as the cells will settle 
rapidly. Distribute cells equally by moving the plate as described above. 
10. Add 5mL GM to the remaining 1mL cell suspension in the Falcon tube and mix gently to 
resuspend cells. 
11. Seed each well of a 24 well plate containing 250μL pre-equilibrated media per well with 
250 μL suspended cells.   
12. Incubate 37C/5%CO2/Air for 24 hours. 
13. Perform passage 1 baseline confluence scan using Celigo® S imaging cytometer; return 
to incubator. 
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14. Aspirate media and replace with 500mL GM containing fresh bFGF every 2 days. 
15. Perform confluence scan daily until confluence reaches 70-75%. 
Note: Passage 2 cultures often do not have a lag phase. 
 
Passage 3: Trypsinization, splitting and cryopreservation of passage 2 cultures 
1. When confluence scan shows cells to be 75-80% confluent in all 24 wells of the passage 
1 culture, pre-equilibrate one entire collagen coated 24 well plate with 250μL GM per 
well and five (5) collagen coated 10cm plates with 8mL GM per plate for a minimum of 
two hours. 
2. Aspirate media from the 24 passage 2 wells. 
3. Add 250μL 0.25% Trypsin-EDTA to each of 24 wells.  
4. Return to incubator for 3-5 minutes, placing each plate in direct contact with the metal 
shelf of the incubator. 
5. Remove the five 10cm plates from the incubator and aspirate the media. 
6. Add 2mL 0.25% Trypsin-EDTA to each 10 cm plate, ensuring the media is distributed 
evenly over the entire surface. 
7. Return the five 10 cm plates to the incubator, placing each plate in direct contact with the 
metal shelf of the incubator. 
8. Immediately check the 24 well plate for detachment using the EVOS. The cells should be 
detached by this time. 
9. Pool the contents of the 24 wells and transfer the resulting 6mL of cells suspended in 
0.25% Trypsin-EDTA to a 15mL Falcon.  
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10. Rinse all wells with an additional 6mL (250μL per well) fresh GM and add to falcon tube 
labeled with the participant number and “24”. 
11. Place on ice.  
12. Immediately check one 10 cm plate for detachment using the EVOS. The cells should be 
detached by this time. 
13. Remove the cells from each 10cm dish by holding the plate at an angle and rinsing the 
plate surface with the 2 mL trypsin solution, allowing it to collect at the bottom edge of 
the dish. Transfer the contents of each dish to a 15mL falcon tube (10mL total) labeled 
with the participant number and “10”. 
14. Add 2mL FBS to the falcon tube to neutralize the trypsin and balance the tube with the 
pooled cells from the 24 well plate. Place on ice. 
15. Centrifuge both tubes at 300rcf for 5min at RT. 
16. Aspirate supernatant from each pellet and dislodge the pellet. The pellet from the “10” 
tube should be approximately 5 times the size of the “24” tube.   
17. Resuspend each pellet with 1mL GM per “10 cm plate”, meaning resuspend the “24” 
pellet in 1 mL GM and resuspend the “10” pellet with 5 mL GM. 
18. Place both suspensions on ice. 
19. Dilute 10μL from each cell suspension 1:10 in Moxi Z Diluent and determine the number 
of cells in each culture. There should be the same number of cells per mL at this point. 
Record the cell concentration. 
20. Pool the two suspensions into one tube and mix gently. 
21. Cryopreservation 
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a. For passage 3 cryopreservation, prepare 8 sterile cryovials and label (Side: Study 
ID, Participant number, P3, Date; Top (insert) Participant number, P3). In 
the BSC, open all of the tubes and place them in a white Styrofoam rack.  
b. In a 50mL Falcon tube, prepare cryopreservation media by combining 3mL GM 
with 800μL DMSO. Chill on ice.  
c. Working rapidly but pipetting gently, transfer 5mL of the cell suspension to the 
prepared cryopreservation media and mix by gentle trituration. The concentration 
of DMSO is now 10%. 
d. Immediately distribute the suspension equally to the open cryotubes, cap the 
tubes, transfer them to a controlled rate isopropanol chiller (Mr. Frosty) and place 
in a -80°C freezer for a minimum of 4 h before transferring cultures to storage 
boxes.  
22. Add 5mL GM to the remaining 1mL cell suspension in the Falcon tube and mix gently to 
resuspend cells. 
23. Retrieve the five 10 cm plates containing 8 mL pre-equilibrated GM from the incubator 
and add 1mL cell suspension to each. Be sure to gently mix the suspension before 
pipetting as the cells will settle rapidly. Distribute cells equally by moving the plate as 
described above. Return plates to the incubator. 
24. Add 5mL GM to the remaining 1mL cell suspension in the Falcon tube and mix gently to 
resuspend cells. 
25. Retrieve the prepared 24 well plate containing 250μL pre-equilibrated media per well 
from the incubator and seed each well with 250μL suspended cells.  Return plate to 
incubator. 
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26. Incubate 37C/5%CO2/Air for 24 h. 
27. Perform passage 3 baseline confluence scan using Celigo® S imaging cytometer; return 
to incubator. 
28. Aspirate media, replace with 500mL GM containing fresh bFGF every 2 days. 
29. Perform confluence scan daily until confluence reaches 70-75%. 
 
Passage 4: Trypsinization and cryopreservation of passage 3 cultures 
1. When the confluence scan shows cells to be 75-80% confluent in all 24 wells of the 
passage 1 culture, prepare 18 cryovials (Side: Study ID, Participant number, P4, Date; 
Top Participant number, P4). 
2. Aspirate media from the 24 passage 2 wells. 
3. Add 250μL 0.25% Trypsin-EDTA to each of 24 wells.  
4. Return to incubator for 3-5 min, placing each plate in direct contact with the metal shelf 
of the incubator. 
5. Remove the five 10cm plates from the incubator and aspirate the media. 
6. Add 2mL 0.25% Trypsin-EDTA to each 10 cm plate, ensuring the media is distributed 
evenly over the entire surface. 
7. Return the five 10 cm plates to the incubator, placing each plate in direct contact with the 
metal shelf of the incubator. 
8. Immediately check the 24 well plate for detachment using the EVOS. The cells should be 
detached by this time. 
9. Pool the contents of the 24 wells and transfer the resulting 6mL of cells suspended in 
0.25% Trypsin-EDTA to a 15mL Falcon tube. 
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10. Rinse all wells with an additional 6mL (250μL per well) fresh GM and add to falcon tube 
labeled with the participant number and “24”. 
11. Place on ice.  
12. Immediately check one 10 cm plate for detachment using the EVOS. The cells should be 
detached by this time. 
13. Remove the cells from each 10cm dish by holding the plate at an angle and rinsing the 
plate surface with the 2 ml trypsin solution, allowing it to collect at the bottom edge of 
the dish. Transfer the contents of each dish to a 15mL falcon tube (10mL total) tube 
labeled with the participant number and “10”. 
14. Add 2mL FBS to the falcon tube to neutralize the trypsin and balance the tube with the 
pooled cells from the 24 well plate. Place on ice. 
15. Centrifuge both tubes at 300rcf for 5min at RT. 
16. Aspirate supernatant from each pellet and dislodge the pellet. The pellet from the “10” 
tube should be approximately 5 times the size of the “24” tube.   
17. Resuspend each pellet with 1mL GM per “10 cm plate”, meaning resuspend the “24” 
pellet in 1 ml GM and resuspend the “10” pellet with 5 mL GM. 
18. Place both suspensions on ice. 
19. Dilute 10μL from each cell suspension 1:10 in Moxi Z Diluent and determine the number 
of cells in each culture.  There should be the same number of cells per mL at this point. 
Record the cell concentration. 
20. Cryopreservation: 
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a. For passage 4 cryopreservation, prepare 16 sterile cryovials and label (Side: 
Study ID, Participant number, P4, Date; Top Participant number, P4). In the 
BSC, open all of the tubes and place them in a white Styrofoam rack.   
b. In a 50mL Falcon tube, prepare cryopreservation media by combining 10mL GM 
with 1600μL DMSO. Chill on ice.  
c. Working rapidly but pipetting gently, transfer all 6mL of the cell suspension to 
the prepared cryopreservation media and mix by gentle trituration. The 
concentration of DMSO is now 10%. 
d. Immediately distribute the suspension equally to the open cryotubes, cap the 
tubes, transfer them to a controlled rate isopropanol chiller (Mr. Frosty) and place 
in a -80°C freezer for a minimum of 4 h before transferring cultures to storage 
boxes.  
 
 FACS sorting cultures to obtain homogeneous living MPCs (CD56+/CD29+)  
1. Pre-equilibrate plates for culture after sorting. Place in incubator 1x24 well 500μL per 
well, 2x10cm, 9mL per plate for each culture. 
2. Two hours prior to sorting, rapidly thaw 1-1.5 million cryopreserved passage 4 cells (1-2 
vials).  
Note: If sorting cultures from more than one participant, handle each culture 
independently, keeping all cell suspensions on ice when not being processed. 
3. Transfer entire contents of cryovials to 15mL falcon tube containing 10mL GM 10mL 
GM into labeled 15mL Falcon tube, labeled with participant number. 
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4.  Mix gently by inversion and place on ice until centrifugation if preparing more than one 
culture. 
5. Centrifuge at 300rcf for 5min at RT. 
6. Aspirate supernatant and dislodge pellet. 
Note: 1-2 million cells should produce a visible pellet. If pellet is not visible, perform a 
cell count with the Moxi and thaw more vials of cells if necessary. Be sure you have 
sufficient cells before processing. 
7. Resuspend pellet in 3mL FACS buffer. 
8. Centrifuge at 300rcf for 5min at RT. 
9. Aspirate supernatant, dislodge pellet. 
10. Resuspend pellet in 250μL FACS buffer. Place on ice. 
11. For Live/Dead controls, pool 50μL from each tube of resuspended cells in a 1.7mL 
microfuge tube. Place on ice until step 16. 
12. From this point on, turn off lights in BSC and protect samples from direct light or 
sunlight. 
13. Prepare antibody cocktail consisting of 5μL CD56 AF488 and 8μL CD56 PE-Cy7 per 
culture (for four cultures combine 21μL CD56 AF488 and 33.6 μL CD56 PE-Cy7). 
14. Add 13μL antibody cocktail to the suspended cells and incubate 30 min in the dark on 
ice. 
15. Prepare Compensation controls for fluorochrome gating. 
a.  Vortex eBeads, one drop =50μL. Prepare a separate control for each antibody. 
b. Combine 1 drop eBeads with 1μL antibody in 1.7mL microfuge tube. 
c. Incubate in the dark on ice for a minimum of 15 min. 
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d. Add 1.5mL FACS buffer to beads and vortex. 
e. Centrifuge 500rcf in microfuge for 5min at RT (to save time, this step can be 
performed at the same time as step 16e). 
f. Locate the pellet. It will move to the bottom of the tube and be difficult to see.  
Aspirate supernatant, and resuspend beads in 200μL FACS buffer. 
g. Transfer antibody conjugated beads to culture tube. Keep on ice in dark. 
16. Prepare live/dead gating controls. 
a. Evenly divide the total volume of pooled cell suspension from step 11 into two 
1.7mL Microfuge tubes. 
b. Label one tube “dead” and add 500μL 70% ethanol to the cell suspension. 
c. Label another tube “live” and add 1.5 ml FACS buffer to the tube. 
d. Add 1mL FACS buffer to the “dead” tube. 
e. Centrifuge 500rcf in microfuge for 5min at RT (to save time, this step can be 
performed at the same time as step 15e). 
f. Aspirate the supernatants. Resuspend each pellet in 150μL FACS buffer.  
g. Pool “live” and “dead” cells in a culture tube. Keep on ice in dark. 
17. Wash cultures stained with antibody cocktail. 
a. Add 10mL FACS buffer to each culture. 
b. Centrifuge 300rcf for 5min at RT. 
c. Aspirate supernatant and dislodge pellet. 
d. Resuspend each pellet in 300μL FACS buffer and transfer to labeled culture tube. 
e. Store on ice in the dark. 
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18. Prepare collection tubes for each culture by pipetting 300μL FACS into two culture tubes 
per culture to be sorted. Label each with the participant number. One should be labeled 
CD56+/CD29+ (++) and the other CD56-/CD29+  (+-). 
19. Perform live/dead staining on live/dead controls and cultures stained with antibody 
cocktail just prior to leaving for the FACS facility. 
a. Add 1μL 7AAD to each culture to be sorted. 
b. Add 1μL 7AAD to live/dead control prepared in step 16. 
20. Transport all samples to FACS facility on ice in the dark. Follow university guidelines 
and regulations for transport. 
21. FACS sort cultures.   
a. Use ND2 filter for mammalian cells. 
b. Compensation beads for CD56, check voltage, record. 
c. Compensation beads for CD29, check voltage, record. 
d. Run compensation controls (each AB and live dead). 
e. Gate based on side/forward scatter and 7AAD negativity.  
f. Sort living cells into ++ and +- populations, and record number of events in each 
category. Use these numbers when seeding cells back into culture plates. 
22. As soon as possible, resuspend the sorted ++ cells for each culture in GM. 
23. Centrifuge at 300rcf for 5min at RT. 
24. Aspirate supernatant, dislodge pellet and resuspend in 1mL GM. 
25. Based on the event count from the FACS sort, seed all cells at recommended densities in 
pre-equilibrated, collagen coated plates.  
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a. Seed all wells of the 24 well plate (if possible) with 10,000 cells per well for 
Celigo Scanning. 
b. Seed 10cm plates with the remainder of the cells (if there are any) at a density of 
~175,000 cells per plate. 
Note: As a rule of thumb, seed one well/plate at higher than the recommended density 
if there are not enough cells to seed two at the recommended density.   
26. Return plates to incubator and culture 37°C/5%CO2/Air for 24 h. 
27. Perform passage 4 ++ baseline confluence scan using Celigo® S imaging cytometer; 
return to incubator. 
28. Aspirate media, replace with 500mL GM containing fresh bFGF every 2 days. 
29. Perform confluence scan daily until confluence reaches 70-75%. 
 
Passage 5: Trypsinization and splitting of cultures 
At this point we find that the rate of proliferation will slow significantly for the CD56+/CD29+ 
culture. These cultures will also show a lag phase, and may also reach a growth plateau before 
reaching 75% confluence. Daily confluence scans will make this easily detectible. If the culture 
shows a growth plateau after exponential growth for two successive days, split the culture. Some 
cultures may proliferate very slowly without reaching a plateau or 75%.  If this is the case split 
the culture after 7 days. 
1. When confluence scan shows the ++ cells for a participant culture to be an average of 75-
80% confluent in the 24 well plate, pre-equilibrate one entire collagen coated 24 well 
plate with 250μL GM per well and five (5) collagen coated 10cm plates with 8mL GM 
per plate per sorted culture for a minimum of two hours.  If any 10 cm plates were 
 141 
seeded, prepare two labeled cryovials per 10 cm plate (Side: Study ID, Participant 
number, P5++, Date; Top (insert) Participant number, P5++). 
2. Aspirate media from the passage 4++ wells of the 24 well plate. 
3. Add 250μL 0.25% Trypsin-EDTA to each of Passage 4 ++ wells of the 24 well plate. 
4. Return to incubator for 3-5 min, placing each plate in direct contact with the metal shelf 
of the incubator. 
5. Remove 10cm plate(s) from the incubator and aspirate the media. 
6. Add 2mL 0.25% Trypsin-EDTA to each 10 cm plate, ensuring the media is distributed 
evenly over the entire surface. 
7. Return the 10 cm plate(s) to the incubator, placing each plate in direct contact with the 
metal shelf of the incubator. 
8. Immediately check the 24 well plate for detachment using the EVOS. The cells should be 
detached by this time. 
9. Pool the contents of the 24 wells and transfer the resulting 6mL of cells suspended in 
0.25% Trypsin-EDTA to a 15mL Falcon. 
10. Rinse all wells with an additional 6mL (250μL per well) fresh GM and add to falcon tube 
labeled with the participant number and “24”. 
11. Place on ice.  
12. Immediately check one 10 cm plate for detachment using the EVOS. The cells should be 
detached by this time. 
13. Remove the cells from each 10 cm dish by holding the plate at an angle and rinsing the 
plate surface with the 2 mL trypsin solution, allowing it to collect at the bottom edge of 
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the dish. Transfer the contents of each dish to a 15mL falcon tube labeled with the 
participant number, and “10”. Add GM to the tube to match the volume of the “24” tube. 
14. Keep cells on ice if processing more than one participant culture.  Process all cultures 
separately, and keep on ice until centrifugation. It is very rare that all four sorted cultures 
will reach the same stage of confluence on the same day. It is often best to process 1-2 
cultures per day/interval, as more than that will lead to mistakes and extended times out 
of the incubator. 
15. Centrifuge for 300rcf for 5min at RT. 
16. Aspirate supernatants, dislodge pellets.  
17. Resuspend “10” pellet in 1mL GM and place on ice until step 22. 
18. Resuspend “24” pellet in 6mL GM, seed plates, and mix gently to resuspend cells. 
19. Retrieve the five 10 cm plates containing 8mL pre-equilibrated GM from the incubator 
and add 1 mL cell suspension to each. Be sure to gently mix the suspension before 
pipetting as the cells will settle rapidly. Distribute cells equally by moving the plate as 
described above. Return plates to the incubator. 
20. Add 5mL GM to the remaining 1mL cell suspension in the Falcon tube and mix gently to 
resuspend cells. 
21. Retrieve the prepared 24 well plate containing 250μL pre-equilibrated media per well 
from the incubator and seed each well with 250μL suspended cells.  Return plate to 
incubator. 
22. Count and cryopreserve any additional cells from the 10 cm plates. 
a. Gently resuspend the cells in the “10” tube and dilute 10μL 1:10 in Moxi Z 
Dilutent and determine the number of cells per mL in the tube.   
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b. In the BSC, open the two prepared cryovials and place them in a white Styrofoam 
rack.  
c. In a 15 ml falcon tube, prepare cryopreservation medium by combining 1mL GM 
with 200μL DMSO and chill on ice. 
d. Add the 1mL “10” cell suspension to the cold cryoprpreservation medium and 
mix gently by pipetting. The concentration of DMSO is now 10%. 
e. Immediately distribute the suspension equally to the prepared cryotubes, cap the 
tubes, transfer them to a controlled rate isopropanol chiller (Mr. Frosty), and place 
in a -80°C freezer for a minimum of 4 h before transferring cultures to storage 
boxes.  
23. Incubate the seeded passage 5++ cells at 37°C/5%CO2/Air for 24 h. 
24. Perform passage 5++ baseline confluence scan using Celigo® S imaging cytometer; 
return to incubator. 
25. Aspirate media, replace with 500mL GM containing fresh bFGF every 2 days. 
26. Perform confluence scan daily until confluence reaches 70-75%. 
 
Passage 6: Trypsinization and cryopreservation of passage 6++ cultures. (This is the same as 
Passage 4.) 
1. When the confluence scan shows cells to be 75-80% confluent in all 24 wells of the 
passage 5++ culture, prepare 16 cryovials. (Side: Study ID, Participant number, P6++, 
Date; Top (insert) Participant number, P6++). 
2. Aspirate media from the 24 passage 5++ wells. 
3. Add 250μL 0.25% Trypsin-EDTA to each of 24 wells.  
 144 
4. Return to incubator for 3-5 minutes, placing each plate in direct contact with the metal 
shelf of the incubator. 
5. Remove the five 10cm plates from the incubator and aspirate the media. 
6. Add 2mL 0.25% Trypsin-EDTA to each 10 cm plate, ensuring the media is distributed 
evenly over the entire surface. 
7. Return the five 10 cm plates to the incubator, placing each plate in direct contact with the 
metal shelf of the incubator. 
8. Immediately check the 24 well plate for detachment using the EVOS. The cells should be 
detached by this time. 
9. Pool the contents of the 24 wells and transfer the resulting 6mL of cells suspended in 
0.25% Trypsin-EDTA to a 15mL Falcon tube. 
10. Rinse all wells with an additional 6mL (250μL per well) fresh GM and add to falcon tube 
labeled with the participant number and “24”. 
11. Place on ice.  
12. Immediately check one 10 cm plate for detachment using the EVOS. The cells should be 
detached by this time. 
13. Remove the cells from each 10cm dish by holding the plate at an angle and rinsing the 
plate surface with the 2 mL trypsin solution, allowing it to collect at the bottom edge of 
the dish. Transfer the contents of each dish to a 15mL falcon tube (10mL total) tube 
labeled with the participant number and “10”. 
14. Add 2mL FBS to the falcon tube to neutralize the trypsin and balance the tube with the 
pooled cells from the 24 well plate. Place on ice. 
15. Centrifuge both tubes at 300rcf for 5min at RT. 
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16. Aspirate supernatant from each pellet and dislodge the pellet. The pellet from the “10” 
tube should be approximately 5 times the size of the “24” tube.   
17. Resuspend each pellet with 1mL GM per “10 cm plate”, meaning resuspend the “24” 
pellet in 1 mL GM and resuspend the “10” pellet with 5 mL GM. 
18. Place both suspensions on ice. 
19. Dilute 10μL from each cell suspension 1:10 in Moxi Z Diluent and determine the number 
of cells in each culture.  There should be the same number of cells per mL at this point. 
Record the cell concentration. 
20. Cryopreservation: 
a. In the BSC, open all 16 of the prepared cryovials and place them in a white 
Styrofoam rack. 
b. In a 50mL Falcon tube, prepare cryopreservation media by combining 10mL GM 
with 1600μL DMSO. Chill on ice.  
c. Working rapidly but pipetting gently, transfer all 6mL of the cell suspension to 
the prepared cryopreservation media and mix by gentle trituration. The 
concentration of DMSO is now 10%. 
d. Immediately distribute the suspension equally to the open cryotubes, cap the 
tubes, transfer them to a controlled rate isopropanol chiller (Mr. Frosty) and place 
in a -80°C freezer for a minimum of 4 hours before transferring cultures to storage 
boxes.  
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FACS Protocol 
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Live/Dead Staining 
Cell staining 
1. Prepare propidium iodide and Hoechst mixed dye solution (6mL F12 + 6μL propidium 
iodide + 2 μL Hoechst). 
2. Remove media from all wells and add 200 μL of mixed dyes solution. 
3. Incubate cells for 20 min at 5% CO2, 37 °C. 
4. Remove media from all wells and add 200 μL of F12. 
5. As cells are live in the wells, the place should be imaged immediately on the Celigo. 
Celigo imaging 
1. Create a new scan and name file appropriately 
2. Scan Tab: Select Celigo Application: Cell Viability (live + dead + total) 
3. Setup Live Channel 
a. Select Brightfield Channel 
b. Auto exposure 
c. Register Auto 
4. Setup Dead Channel 
a. Select Red illumination for Propidium Iodide stain 
b. Auto exposure 
c. Set offset 
5. Setup Total Channel 
a. Select Blue illumination for Hoescht stain 
b. Auto exposure 
c. Set offset 
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6. Start scan 
 
RNA Isolation 
1. Heat water to 56°C 
2. Run lysate (prepared with buffer TRK) through homogenizer column 
3. Spin; 10,000 g; 1 minute (keep filtrate!) 
4. Add one volume 70% ethanol; mix gently by repipetting 
5. Transfer to spin column (orange); 10,000 g; 1 minute 
6. Discard filtrate (the RNA is now attached to filter column) 
7. Add 250 μL RNA wash buffer 1 to orange column reservoir; 10,000 g; 1 minute 
8. Discard filtrate 
9. DNAse Digest: Apply 75 μL DNAse solution to the column membrane; incubate 15 min 
on bench 
a. Prepare DNAse solution: 10 μL DNAse stock + 70 μL buffer RDD for each 
sample to be treated 
b. 6 samples: 60 μL DNAse stock + 42 μL buffer RDD 
10. Add 250 μL RNA wash buffer 1 to column reservoir; 10,000 g; 1 minute 
11. Discard filtrate 
12. Add 500 μL wash buffer II to column reservoir; 10,000 g; 1 minute 
13. Discard filtrate 
14. Add 500 μL wash buffer II to column reservoir; 10,000 g; 1 minute 
15. Discard filtrate 
16. Spin empty column 10,000 g; 2 minutes 
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17. Apply 50 μL RNAse free water to column membrane heated to 56 degrees; incubate 5-15 
minutes on bench – this will allow the RNA to detach from the membrane in the column  
18. Elute RNA by spinning into clean conical tube (cut the top off) 10,000g; 1 minute 
19. Keep RNA on ice or colder 
Spectromax 
1. Plate reader has 24 spots 
2. Top left corner, put blank  
3. Set machine to blank to that 
4. Load samples (2.5 μL)  
5. Protocol on desktop (5 mm RNA?) 
6. Run  
 
cDNA Synthesis from RNA by Reverse Transcription 
RNA can be reverse transcribed into cDNA using reverse transcriptase. RNA expression can 
then be quantified using the cDNA and quantitative PCR (RT-qPCR). 
1. Determine RNA dilutions: Using the High Capacity cDNA Synthesis Kit from Applied 
Biosciences, you can load a maximum of 2 μg of RNA per reaction. If you have low 
concentrations or volumes of RNA, load 1 μg (or less) of RNA per reaction instead  
2. Label tubes: Use the small 0.2 mL thin walled PCR tubes , one tube per sample. Also get 
one larger tube for the RT master mix.  A no template control should also be made with 
10μL of RT master mix and 10 μL nanopure water.  
3. Prepare 2X RT master mix: Make enough for 1 extra reaction to account for pipetting 
error. Use filter tips for PCR.  
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Component Volume per reaction 
(μL) 
Volume for ___ reactions 
(μL) 
10X RT Buffer 2.0  
25X dNTP mix 0.8  
10X RT random primers 2.0  
Multiscribe Reverse 
Transcriptase 
1.0  
Nuclease-free H2O 4.2  
TOTAL 10.0  
 
4. Add water and RNA sample: Use the RNA dilutions sheet to load the appropriate amount 
of nanopure water, followed by the RNA sample. There should be 10 μL total of RNA + 
water. 
5. Add 10 μL of 2X RT Master Mix to each tube. 
6. Program the Bio-Rad Thermal cycler: Using the Bio-Rad T100-Thermocycler in room 
140 Kinzelberg and run pr otocol: AB-HC-RT. The program should have the following 
parameters: 
1. 25⁰ C for 10 minutes 
2. 37⁰ C for 120 minutes 
3. 85⁰ C for 5 minutes 
4. 4⁰ C 
7. Load samples and run RT reaction: Spread out your samples evenly. Start the PCR run, 
and come back in two hours for your cDNA. 
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RT-PCR  
The following directions were written for TaqMan Fast Advanced Master Mix 
1. Thaw Taqman Fast Advanced Master Mix, Taqman Prime/probes and dilute cDNA 
sample at room temperature 
2. Use the PCR MM Calculator (see ATM Lab Protocol Folder > RT-PCR for a copy) to 
calculate appropriate volumes 
3. In one tube make enough master mix (water + Taqman Master Mix + Primer/probe) for 
all samples 
4. Vortex and spin the master mix 
5. Aliquot 64.8 μL to a set of tubes – one tube for each sample 
6. Vortex and spin the cDNA 
7. Add 7.2μL cDNA to each tube of aliquoted master mix 
8. Vortex and spin each reaction tube (master mix + cDNA) 
9. Pipette 20μL of each reaction into 3 wells of a 96 well plate 
10. Cover the plate with a clear cover 
11. Spin the plate on the centrifuge on the second floor at 1000 rpm for 1 minute 
12. Read the plate on the LightCycler480 on the 3rd floor 
 
Seahorse Flux Analysis 
1. Hydrate cartridge 12+ hours prior to assay in non CO2 incubator 
2. Prepare unbuffered assay medium: pH to7.4 @ 37 degrees 
3. Warm assay medium to 37 degrees in non-CO2 incubator 
4. Prepare injectable compounds using assay medium to 7.4 @ 37 degrees 
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a. 50 μL oligomycin + 50 μL  FCCP + 400 μL medium 
5. Check cells under microscope 
6. Replace cell culture medium with assay medium 
7. Place cells in assay medium into non-CO2 incubator for 30+ minutes prior to assay run 
8. Load injectable compounds (56 μL) into port A  
9. Place cartridge and utility plate with calibration buffer into XF Analyzer 
10. Run protocol from template to calibrate cartridge 
11. Upon completion of cartridge calibration, load cell culture plate into instrument 
12. Continue to run assay protocol 
13. Upon completion of run, complete live/dead stain 
a. 1 mL media + 20 μL propidium iodide + 5 μL Hoescht  spike 25 μL per well  
b. Incubate 20-30 minutes 
c. Read on Celigo  
14. Normalize ECAR and OCR readings to live cell count in each well 
 
Glucose Uptake  
1. Make 2DPG Detection Reagent 1 hr prior to use 
a. Luciferase, 3300 μL 
b. NADP+, 33 μL 
c. G6PDH, 82.5 μL 
d. Reductase, 16.5 μL 
e. Reductase substrate, 2.06 μL 
2. Remove media, wash with 100 μL glucose free media 
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3. Add 50 μL 2DG Detection Reagent media/well  
4. Add 50 μL glucose free media to background wells 
5. Spike 25 μL Hoescht dilution in normalization row  incubate  read celigo 
6. Wash normalization row and add 50 μL glucose free media 
7. After 1 hr of 2DG incubation, add stop buffer, neutralization buffer, detection buffer 
8. Read luminescence after 1 hour incubation 
 
Puromycin 
1. Stock = 25 mg/mL 
2. Dilute 1:1000 
3. Add 202.5 μL of 1:1000 diluted stock + 922.5 μL media 
4. Spike 25 μL of dilution into each well 
5. Leave 20 min 
6. Aspirate 
7. Add 150 μL Paraformaldehyde 
8. Leave 20 min 
9. Aspirate 
10. Add 150 μL sodium azide per well 
11. Wrap plate with parafilm and store in refrigerator 
12. Wash 5x with 200 μL 0.1% Triton X-100 solution in 1X PBS at RT 
13. Block with 150 μL Odyssey Blocking Buffer for 1.5 h at RT 
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14. Add 50 μL diluted antibody (1:1000) to all wells except controls. Add 50 μL Odyssey 
Blocking Buffers to control wells. Incubate for 2.5 h at RT or overnight at 4 degrees C 
with gently shaking.  
15. Wash 5x with 200 μL 0.1% Tween 20 in 1x PBS solution at RT 
16. Add 50 μL diluted secondary antibody/ cell tag 700 to all wells except the control well. 
Add 50 μL diluted secondary antibody to the control wells. Wash 5x with 200 μL 0.1% 
Tween 20 in 1x PBS solution at RT 
17. After final wash, completely remove solution from wells; scan immediately on Licor or 
store from light at 4°C 
 
R Code  
Code for Paper: Expansion capacity of human muscle progenitor cells differs by age, sex, and 
metabolic fuel preference 
 For variables: percent dead tAUC, live nuclei nAUC, confluency nAUC, saturation density, 
population doubling time, baseline OCR, stressed OCR, OCR metabolic potential, baseline 
ECAR, stressed ECAR, ECAR metabolic potential, OCR/ECAR ratio, and glucose uptake: 
library(lme4) 
library(ggplot2) 
library(lsmeans) 
library(pbkrtest) 
my_data<-read.csv("Growth_Metabolic_R.csv") 
str(my_data) 
table(my_data$Age, my_data$Sex) 
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install.packages("car") 
library(car) 
View(my_data) 
#Run the ANOVA 
ANOVA_PDT<-aov(PDT ~ Age*Sex, data=my_data) 
Anova(ANOVA_PDT, type="III") 
#Compute summary statistics 
model.tables(ANOVA_PDT, type="mean", se=TRUE) 
#Multiple comparisons if interaction is significant 
TukeyHSD(ANOVA_PDT) 
#Check homogeneity of variance assumption 
plot(ANOVA_PDT) 
leveneTest(PDT ~ Age*Sex, data=my_data) 
plot(ANOVA_PDT,2) 
#extract residuals 
aov_residuals<-residuals(object=ANOVA_PDT) 
shapiro.test(x=aov_residuals) 
 
 For variables: percent dead, live nuclei count, and percent confluency over time: 
library(lme4) 
library(ggplot2) 
library(lsmeans) 
library(pbkrtest) 
 157 
library(emmeans) 
my_data<-read.csv("Curves_For_R.csv") 
str(my_data) 
table(my_data$Age, my_data$Sex) 
install.packages("car") 
library(car) 
View(my_data) 
#Run the ANOVA 
ANOVA_Nuclei<-aov(Confluency ~ Group*as.factor(Time), data=my_data) 
Anova(ANOVA_Nuclei, type="III") 
#For pairwise testing in linear model at each time point 
Nuclei.lm<-lmer(Confluency ~ Group*as.factor(Time) +(1|Sample), data=my_data) 
Anova(Nuclei.lm, type="III") 
emmeans(Nuclei.lm, pairwise~Group|as.factor(Time), at=list(Time=c(24,48,72,96,120))) 
 
#Pairwise and adjust 
Nuclei.emm<-emmeans(Nuclei.lm, pairwise~Group|as.factor(Time),adjust="bonferroni") 
Nuclei.summary<-summary(Nuclei.emm$contrast) 
Nuclei.summary 
 
 For variables: mRNA levels of PPARGC1α, CD36, GLUT1, and GLUT4 over time: 
library(lme4) 
library(ggplot2) 
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library(lsmeans) 
library(pbkrtest) 
my_data<-read.csv("PCR_Metabolic_R.csv") 
str(my_data) 
table(my_data$Age, my_data$Sex) 
install.packages("car") 
library(car) 
View(my_data) 
#convert time to a factor 
my_data$Time<-factor(my_data$Time, levels=c(1,2)) 
#Run the ANOVA 
ANOVA_GLUT4<-aov(GLUT4 ~ Age*Sex*Time, data=my_data) 
Anova(ANOVA_GLUT4, type="III") 
#If interaction is not significant, replace * with + (additive model) 
#Compute summary statistics 
model.tables(ANOVA_LN_96, type="mean", se=TRUE) 
#Multiple comparisons if interaction is significant 
TukeyHSD(ANOVA_GLUT4) 
#Check homogeneity of variance assumption 
plot(ANOVA_PDT) 
leveneTest(PDT ~ Age*Sex, data=my_data) 
plot(ANOVA_PDT,2) 
#extract residuals 
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aov_residuals<-residuals(object=ANOVA_GLUT1) 
shapiro.test(x=aov_residuals) 
 
 
Code for Paper: Transcript profile distinguishes variability in human myogenic progenitor cell 
expansion capacity 
 For variables: confluency, live nuclei count, and percent dead over time: 
library(lme4) 
library(ggplot2) 
library(lsmeans) 
library(pbkrtest) 
library(emmeans) 
my_data<-read.csv("Curves_For_R.csv") 
str(my_data) 
table(my_data$Age, my_data$Sex) 
install.packages("car") 
library(car) 
View(my_data) 
#Run the ANOVA 
ANOVA_Nuclei<-aov(Confluency ~ Group*as.factor(Time), data=my_data) 
Anova(ANOVA_Nuclei, type="III") 
#For pairwise testing in linear model at each time point 
Nuclei.lm<-lmer(Confluency ~ Group*as.factor(Time) +(1|Sample), data=my_data) 
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Anova(Nuclei.lm, type="III") 
emmeans(Nuclei.lm, pairwise~Group|as.factor(Time), at=list(Time=c(24,48,72,96,120))) 
 
#Pairwise and adjust 
Nuclei.emm<-emmeans(Nuclei.lm, pairwise~Group|as.factor(Time),adjust="bonferroni") 
Nuclei.summary<-summary(Nuclei.emm$contrast) 
Nuclei.summary 
 
Code for Paper: RNA Transcript profile distinguishes human muscle progenitor cell 
inflammatory susceptibility 
 For variables puromycin and mRNA: 
library(lme4) 
library(ggplot2) 
library(lsmeans) 
library(pbkrtest) 
my_data<-read.csv("PCR_and_Puromycin.csv") 
str(my_data) 
table(my_data$Age, my_data$Sex) 
install.packages("car") 
library(car) 
View(my_data) 
#Run the ANOVA 
ANOVA_PDT<-aov(PDT ~ Age*Sex, data=my_data) 
 161 
Anova(ANOVA_PDT, type="III") 
#If interaction is not significant, replace * with + (additive model) 
#Compute summary statistics 
model.tables(ANOVA_Con_408, type="mean", se=TRUE) 
#Multiple comparisons if interaction is signifcant 
TukeyHSD(ANOVA_PDT) 
#Check homogeneity of variance assumption 
plot(ANOVA_PDT) 
leveneTest(PDT ~ Age*Sex, data=my_data) 
plot(ANOVA_PDT,2) 
#extract residuals 
aov_residuals<-residuals(object=ANOVA_PDT) 
shapiro.test(x=aov_residuals) 
 
 
 
